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The Blomia tropicalis (Blo t) dust mite is prevalent in tropical and sub-tropical 
regions of the world. Although it is a leading cause of asthma, little is known how it 
induces allergy. Using a novel murine asthma model induced by intra nasal exposure 
to Blo t, we observed that a single intranasal sensitization to Blo t extract induces 
strong Th2 priming in the lung draining lymph node. Resident CD11b+ DCs 
preferentially transport antigen from the lung to the draining lymph node and are 
crucial for the initiation of Th2 CD4+ T cell responses. As a consequence, mice 
selectively deficient in CD11b+ DCs exhibited attenuated Th2 responses and more 
importantly did not develop any allergic inflammation. Conversely, mice deficient in 
CD103+ DCs and CCR2-dependent monocyte-derived DCs exhibited similar allergic 
inflammation compared to their wildtype counterparts. We also show that CD11b+ 
DCs constitutively express higher levels of GM-CSF receptor compared to CD103+ 
DCs and are thus selectively licensed by lung epithelial-derived GM-CSF to induce 
Th2 immunity. Taken together, our study identifies GM-CSF licensed CD11b+ lung 
DCs as a key component for induction of Th2 responses and represents a potential 
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CHAPTER 1: Introduction 
 
1.1 Asthma  
Asthma is a heterogeneous inflammatory disorder of the airways characterized by 
symptoms such as recurrent wheezing, coughing and shortness of breath. These 
clinical manifestations are caused by the obstruction of airflow and narrowing of 
respiratory tract resulting from bronchial smooth muscle constriction, airway 
thickening and mucus hyper-secretion (Kim et al., 2010). The prevalence of asthma 
keeps increasing and currently affects millions of people worldwide. Apart from 
imposing a social burden in terms of quality of life, the cost of asthma patient health 
care also places a significant burden on public health and thus represents a major 
public health concern.  
1.1.1 Asthma as a major public asthma problem 
Approximately, 300 million people suffer from asthma and its prevalence has been 
increasing over the past few decades (Braman, 2006). The increase in asthma and 
atopic diseases has been described as an epidemic event. According to statistics 
released by American Academy of Allergy Asthma and Immunology, the prevalence 
of asthma is particularly high in developed countries with highest prevalence in the 
United Kingdom and New Zealand (Masoli et al., 2004). In developing countries, 
asthma prevalence is increasing sharply with the progress of urbanization. The 
increase in China and India will lead to a dramatic increase in the economic burden 
due to their giant populations (Masoli et al., 2004). Specifically, the high prevalence 




rate has markedly increased the cost of this disease as measured in health care dollars, 
time away from work and school, and mortality. The global economic costs for 
asthma patient care exceed those of tuberculosis and AIDS combined and comprise 
1-2% of total healthcare budget in developed countries (Burr et al., 1999). This 
epidemic increase in asthma has been attributed to aspects of Western culture and 
living styles, including outdoor and indoor air pollution, childhood immunizations, 
and cleaner living conditions, but no single cause has been identified. Over the years, 
asthma has become the focus of public health; meanwhile, research initiatives to 
improve awareness and compliance with medications and to understand the causes 
and course of disease are being implemented gradually (Cohn et al., 2004). 
1.1.2 Asthma as a complex disease caused by multiple factors 
Asthma is featured by complex traits caused by multiple environmental factors in 
combination with more than 100 susceptibility genes and has various forms or 
phenotypes (Umetsu et al., 2002). These phenotypes include allergic asthma induced 
by allergens from dust mite, pollen, ragweed, cockroach, mold and non -allergic 
asthma induced by exposure to ozone, cigarette smoke, diesel exhaust particles, 
obesity, aspirin and exercise, cold air and infection (Kim et al., 2010). These different 
pathways and phenotypes often coexist and act in synergy in patients, although 
distinct pathogenic mechanisms probably underlie different pathways and phenotypes. 
Besides, genes such as IL-13R, IL-4, HLA, IL-10, CD14 and ADAM 33 are involved 
in development of spontaneous asthma (von Mutius, 2009). 




Clinically, asthma is usually classified according to the frequency and severity of 
symptoms, forced expiratory volume and peak expiratory flow rate. In asthma 
research, nevertheless, it is more commonly classified according to the origin and 
cause of the disease, namely allergic asthma and non-allergic asthma as described 
earlier (Romanet-Manent et al., 2002). Allergic asthma, the most common type of 
asthma experienced by approximately 80% of asthmatic patients, is more widely 
investigated and will be the focus of our study. 
1.1.3 Asthma as a chronic inflammatory disease 
Asthma is a chronic inflammatory disease of the airway characterized by airway 
hyper-responsiveness (AHR), recurrent episodes of airway obstruction and wheezing 
(Cohn et al., 2004). The presence of eosinophilic infiltration in the airway has been 
known for almost 100 years, since the first patient died of asthma was reported in 
1908 (Tillie-Leblond et al., 2009). However, inflammation was not considered to be a 
cause of asthma until recently. In early 1980s, the development of flexible, fiberoptic 
bronchoscopy advanced evaluation of the airways of asthmatic patients with 
well-defined lung function during steady state disease. Insightful studies revealed that 
inflammation of the airway was always present, even when patients were 
asymptomatic. Seminal papers describing CD4 T cell subsets and their functional 
effects were published in the late nineteen eighties (Kim et al., 1985; Mosmann et al., 
1986). Subsequent studies showed that Th2 cells were present in the airway of 
asthmatic patients (Robinson et al., 1992). These findings, altogether with the 
association of Th2 cytokines and allergic diseases, led to the theory that Th2 cells 




promote asthma. Over the past 20 years, asthma research has therefore almost 
exclusively focused on inflammation as a cause of disease.  
1.1.4 Clinical symptoms of asthma  
Allergic asthmatic patients experience symptoms such as coughing, wheezing, 
shortness of breath and chest tightness when exposed to allergens. These symptoms 
are highly related to the ongoing eosinophilic inflammation in the airways 
(Tillie-Leblond et al., 2009). In chronic asthma patients, there are structural changes 
in the airways, namely airway remodeling, characterized by subepithelial and airway 
wall fibrosis, goblet cell hyperplasia, and smooth muscle thickening with increased 
vascularity (Bousquet et al., 2000; Fish and Peters, 2000). Airway remodeling occurs 
when the asthma patient is repeatedly exposed to allergen and chronic inflammation is 
progressively induced (Zosky and Sly, 2007). Symptoms of coughing and wheezing 
can be clinically quantified; however, chest tightness, sputum eosinophilia and 
specific exercise-related symptoms have not yet been consistently measured and 
analyzed (Bacci et al., 2006; Green et al., 2002). As symptoms of coughing and 
wheezing are not unique to allergic asthma, patients are usually interviewed about the 
incidence of symptoms, their day/night time occurrence and history of allergy and so 
on to facilitate the diagnosis of asthma. 
1.2 Animal model of asthma  
Clinical observations on asthmatic patients have laid the foundation knowledge for 
scientific studies on the pathogenesis of asthma. At the very beginning, association 




between clinical symptoms and the presence of eosiophilic infiltration, Th2 cytokines 
and CD4 T subsets provided the most valuable evidence on the critical roles of these 
immune components. Recent years, with the burgeoning of biomedical technologies 
such as high-throughput DNA sequencing and gene expression analysis, many new 
genes which trigger the onset of intrinsic asthma, intertwine with environmental 
factors or directly contribute to the pathogenesis have been identified from samples 
obtained from asthmatic patients. Moreover, numerous clinical trials aiming at the 
development of promising therapeutic agents are ongoing. Nevertheless, due to ethical 
reasons, causal relationship between suspected factors and asthma could never be 
determined through clinical and mechanistic studies which are required in the search 
of crucial pathways and drugs. Thus, to achieve deeper understanding of the 
underlying mechanisms in asthma pathogenesis, to identify new drugs and to develop 
effective vaccines, replicable animal models are essential. Since very few laboratory 
animals have been reported to develop asthma-like symptoms spontaneously 
(Szelenyi, 2000), inducible asthma models have been developed with sensitization 
and challenge protocol to achieve the closest mimicking of the cause and progression 
of human asthma.  
Although different laboratory animals such as guinea pigs, dogs, sheep, rats have been 
implemented in asthma research, mice are the most commonly used in experimental 
models because of advantages such as the availability of various transgenic animals, 
the wide array of reagents available for analysis, the low cost of maintenance and the 




relative ease of sensitization to various antigens (Fattouh et al., 2005; Nials and Uddin, 
2008).  
As asthma is such a complex disease with high heterogeneity, influenced by multiple 
environmental factors and genetic factors, it is unlikely that one single animal model 
could resemble all the morphological and functional changes that typify human 
asthma. Therefore, different asthma models have been developed tailored to address 
different scientific questions. Major variations derive the timing and magnitude of the 
inflammatory response in different models, which appear to be related to the duration 
of antigen exposure, the choice of antigen, the route of administration and antigen 
dose, as well as the strain of mice used.  
In this introduction, we focus on describing the difference between chronic and acute 
asthma models, acute ovalbumin asthma model (ovalbumin as antigen) and acute dust 
mite model (dust mite allergen as antigen), which is the most relevant for this study. 
1.2.1 Chronic asthma model vs acute asthma model 
For years, attempts have been made to induce chronic asthma in mice (Kumar and 
Foster, 2001). These chronic asthma models have involved either repeated 
intratracheal/intranasal administration or uncontrolled inhalational exposure to 
antigen (aerosol antigen inhalation) for up to 12 weeks (Johnson et al., 2004; Kim et 
al., 2006; Wegmann, 2008). Chronic airway changes, such as subepithelial fibrosis, 
have usually been induced successfully, but the morphological features have often 
been complicated by development of granulomatous inflammation in the pulmonary 
parenchyma. Moreover, in some experimental systems, down-regulation of 




inflammation and/or airway hyper-responsiveness has been observed after long-term 
exposure to antigen, greatly limiting their usefulness.  
Acute exposure models of bronchopulmonary inflammation are probably more widely 
used and most appropriately employed for investigation of the development and 
regulation of allergic responses (Holt et al., 1999; Nials and Uddin, 2008). The 
availability of cytokine gene knockout mice has greatly facilitated such studies, which 
have yielded important data about pathogenetic mechanisms. Acute antigen exposure 
over a relatively short period of time (2 to 6 weeks) elicits a marked inflammatory 
response in the lung parenchyma, featured by eosinophil and lymphocyte recruitment 
into the airway, mucus hyper-secretion and airway hyper-responsiveness. As a model 
of asthma, however, experimental acute allergic inflammation of the lung parenchyma 
has significant limitations. Characteristic features airway remodelling of human 
asthma such as intraepithelial recruitment of eosinophils, lamina propria inflammation 
and subepithelial fibrosis are virtually absent in these models.  
1.2.2 Ovalbumin asthma model vs dust mite asthma model 
For years, conventional animal sensitization models have relied heavily on a 
non-respiratory allergen-ovalbumin (OVA) (chicken egg-derived antigen) used in 
tandem with artificial chemical adjuvant (typically aluminium hydroxide) via 
systemic sensitization (intraperitoneal) (Boyce and Austen, 2005; Kumar et al., 2008).  
Although these conventional models are able to generate unequivocal allergic airway 
inflammation, namely eosinophilia in the airway, predominant Th2 cytokine 
production, enhanced serum immunoglobulin E, mucus hyper-secretion and even 




airway hyper-responsiveness (AHR), when it comes to the underlying mechanism of 
Th2 immunity initiation, they serve as poor models to elucidate the subtle elements 
required to elicit airway inflammation. This is because the nature of the allergen and 
the route of sensitization can significantly influence the overall innate and adaptive. 
Furthermore, not only does respiratory exposures to OVA lead to inhalation tolerance , 
but continuous challenge with OVA via intranasal route in already sensitized animal 
results in an attenuation and even complete abrogation instead of an increase or 
maintenance of airway inflammation (Akbari et al., 2001).  
Therefore, it is imperative to establish experimental animal models using real-life 
aeroallergens, administered solely via the respiratory route as this will have more 
clinical relevance to explore the underlying mechanisms of the initiation and 
development of Th2 responses. 
As a significant source of indoor allergens, house dust mite (HDM) has been 
identified for its contribution to atopic symptoms in 10% of individuals (Neeno et al., 
1996). Allergy to Dermatophagoides pteronyssinus (Der p) species of house dust mite 
accounts for a large percentage of asthma cases in European countries and Northern 
America (O'Brien et al., 1992). In recent years, experimental animal models using Der 
p has gained popularity as an inducer of allergic response through respiratory 
sensitization and challenge and has even led to the identification of several 
mechanisms underlying Der p’s allergenicity (Chapman et al., 2007; Schulz et al., 
1998; Shakib et al., 1998; Trompette et al., 2009; Wan et al., 1999).  




Nevertheless, although Der p is one of the most prevalent dust mite species in the 
temperate regions where these research was carried out, less focus has been given to 
another major dust mite Blomia tropicalis (Blo t), which is dominant in tropical and 
sub-tropical regions (Arruda et al., 1997; Fernandez-Caldas et al., 1993). High 
frequencies of reactivity to Blo t antigens through skin prick tests have been described 
in asthma and rhinitis patients in these regions and over 20 allergens have been 
identified from asthmatic patient samples through IgE binding activity essay (Castro 
Almarales et al., 2006; Rizzo et al., 1997; Sanchez-Borges et al., 2003; Tsai et al., 
1998). However, most of these allergens only have 30-40% sequence identity with 
their Der p counterparts and share low IgE cross reactivity (Chew et al., 1999). Thus, 
sensitization to Blo t allergens is considered as an independent cause of allergy and 
exhibits distinct immunology. Although experimental mouse models of Blo t 
extract-induced asthma with subcutaneous priming injection have been described and 
characterized, allergic responses elicited by Blo t solely via respiratory route have yet 
to be reported (Baqueiro et al., 2010). In addition, little is known about Blo t shapes 
Th2 responses in Blo t extract-induced asthma models.  
1.3 Overview of allergic asthma: the classic paradigm 
Allergen specific T helper type 2 (Th2) cells are found in the lungs of almost all 
patients asthma, in particularly, patients with allergic asthma (Robinson et al., 1992). 
It is well established that Th2 cells are key players in the pathogenesis of asthma 
through the cytokines they produce (IL-4, IL-5 and IL-13) they mediate several 
hallmarks of asthma/allergy, namely, eosinophilia, goblet cell hyperplasia, airway 




hyper-responsiveness and B cell isotype switching to IgE (Busse et al., 1995; 
Finkelman et al., 2010a; Lewis et al., 2009; Webb et al., 2000; Wills-Karp et al., 
1998).  
Understanding of the role of Th2 cells in asthma has benefited from mouse models of 
allergic asthma. Allergen-specific Th2 cells can be induced in mice, which are 
subsequently recruited into the lungs, causing the development of eosinophilic 
inflammation in the airway and AHR. Typically, mice have been sensitized to a 
number of foreign proteins, such as ovalbumin (OVA), house dust mite extract or 
cockroach extract, as well as fungus and ragweed pollen, by immunization with or 
without exogenous adjuvants such as alum or even low doses of endotoxin. This 
immunization results in Th2 polarization and enhanced allergen-specific IgE 
production. Once sensitization has occurred, repeated administration of allergen into 
the lungs leads to common features of human allergic asthma, such as airway 
eosinophilia, mucus secretion, goblet cell hyperplasia, AHR and, in case of chronic 
models, airway remodelling. Furthermore, adoptive transfer of allergen-specific Th2 
cells generated from OVA-specific T cell antigen receptor–transgenic DO11.10 mice 
results in the development of AHR and airway inflammation (Cohn et al., 1997). In 
contrast, the transfer of allergen specific Th1 (T helper type 1) cells abolishes airway 
eosinophilia and mucus production, although the development of AHR is not 
diminished. Taken together these findings support the idea that Th2 cells producing 
IL-4 and IL-13 have a central role in asthma. 




1.4 Innate immune cells and asthma 
Various innate immune cells, such as macrophages, dendritic cells, nature killer (NK) 
cells, mast cells and granulocytes including basophils, eosinophils and neutrophils, 
have been shown to be involved in asthma in one way or another. For years numerous 
studies have been carried out to investigate their role in asthma. 
Basophils 
Basophils, which develop from hematopoietic stem cells in the presence of IL-3 
(Prussin and Metcalfe, 2006), can be identified as circulating granulocytes expressing 
the high-affinity IgE receptor FcεRI and integrin CD49b (DX5) but not the stem cell 
factor receptor c-Kit (CD117) (Hammad et al., 2010). Aggregation of FcεRI bound by 
multivalent antigens activates basophils for exocytosis and soluble mediator release. 
IL-3, IL-5, GM-CSF and histamine-releasing factor have been shown to prime 
basophils and lead to enhanced degranulation and secretion of IL-4 and IL-13 after 
activation (Prussin and Metcalfe, 2006). IL-33, a member of the IL-1 superfamily, can 
also activate basophils, inducing them to produce IL-4 and IL-13 and potentiates 
degranulation (Pecaric-Petkovic et al., 2009). By releasing histamine, basophils can 
trigger immediate hypersensitivity responses, leading to symptoms like sneezing and 
rhinorrhoea in the upper respiratory tract; cough, bronchospasm, and mucous 
secretion in the lower respiratory tract (Lambrecht and Hammad, 2009).  
More recently, several studies have highlighted a previously unknown role for 
basophils as antigen-presentation cells (APCs) that drive Th2 responses through their 
secretion of IL-4. It has been reported that co-culture of ovalbumin (OVA) antigen 




specific naïve T cells with bone marrow-derived basophils in the presence of OVA 
peptide in the absence of any other APC results in MHC class II–dependent Th2 
differentiation (Sokol et al., 2009). In addition, it has been reported that adoptive 
transfer of basophils into wild-type mice or Ciita–/– mice (which do not express MHC 
class II) followed by antigen challenge induces comparable IL-4 production from 
CD4+ cells, whereas antibody depletion of basophils results in much less IL-4 
production (Perrigoue et al., 2009a; Yoshimoto et al., 2009). Nonetheless, later 
evidence pointed out that the neutralization antibody used to deplete basophils 
actually resulted in a contaminant depletion of dendritic cells which are believed to 
the most important APCs in allergic response (Hammad et al., 2010).  
Eosinophils 
Another prominent circulating granulocyte found at the site of allergic inflammation 
is the eosinophil. Massive recruitment of eosinophils into the airway is considered to 
be one of the hallmarks of allergic inflammation. Eosinophils also develop from 
hematopoietic stem cells. Besides IL-3 and GM-CSF, an additional signal from IL-5 
is required for eosinophil lineage commitment (Rosenberg et al., 2007), which is also 
important for the release of eosinophils from the bone marrow to the peripheral tissue. 
CCL11 acts as a chemoattractant for eosinophils through chemokine C-C motif 
receptor 3. IL-4 together with IL-13 are reported to play important role in 
up-regulating CCL11 (Prussin and Metcalfe, 2006; Rosenberg et al., 2007).  
Following stimulation eosinophils serve an important proinflammatory role by 
producing cysteinyl leukotrienes, as well as Th1 cytokines (interferon-γ and IL-2) and 




Th2 cytokines (IL-4, IL-5, IL-10, IL-13 and tumor necrosis factor) (Hogan et al., 2008; 
Holt et al., 2008). In some but not all experimental models of asthma, eosinophils are 
also required for AHR (Akuthota et al., 2008; Lee et al., 2004), possibly due to the 
activity of IL-13 and cysteinyl leukotrienes or the toxicity of eosinophil granule 
proteins, such as major basic protein, which contributes to airway inflammation. 
Eosinophils, like basophils, are also proposed to be able to function as APCs. It has 
been reported that GM-CSF induces the expression of MHC class II and 
co-stimulatory molecules on eosinophils (Lucey et al., 1989). In an OVA challenge 
model, antigen-loaded eosinophils have been shown to promote the production of 
IL-4, IL-5 and IL-13 by Th2 cells in a dose-dependent manner (MacKenzie et al., 
2001). Although this APC function of eosinophils has been challenged by later studies, 
some of the discrepancies might be explained by the methods used for isolating 
eosinophils that can diminish their antigen processing capacity (Hogan et al., 2008). 
Taken together, these studies indicate that eosinophils have important effector cell 
functions and might also modulate adaptive Th2 immunity.  
Mast cells 
Mast cell, which are related to but distinct from basophils, express FcεRI and c-Kit 
but not CD49b and reside in tissues near mucosal surfaces and blood vessels (Prussin 
and Metcalfe, 2006). Mast cells play a crucial role in initiating immediate 
hypersensitivity reactions by degranulation via antigen-specific IgE cross linking of 
surface receptors, which is one of the central events in the pathogenesis of asthma. 
Upon degranulation, mast cells release an array of inflammatory substances such as 




readily made mediators (histamine, heparin, serine proteases, and proteoglycans) and 
newly-synthesized lipids such as cysteinyl leukotrienes, prostaglandins. In addition, 
mast cells also produce cytokines (IL-1, IL-3, IL-4, IL-5, IL-6, IL-8, IL-10, IL-13, 
IL-16, tumor necrosis factor and transforming growth factor-β) and chemokines (IL-8, 
lymphotactin, CCL1 (TCA-3), CCL5 (RANTES), CCL2 (MCP-1) and CCL3 
(MIP1-α)) (Barrett and Austen, 2009). These cytokines and chemokines are shown to 
be involved in late allergic responses characterized by oedema and cell infiltration 
which play a role in the persistence of asthma. Mast cells can enhance the 
development of asthma in some allergen induced mouse models, and mast 
cell–deficient mouse strains have less AHR, airway inflammation and goblet cell 
hyperplasia and lower concentrations of IgE (Taube et al., 2004; Williams and Galli, 
2000). Like basophils and eosinophils, mast cells have been reported to be able to act 
as APCs, though this function remains poorly understood. IL-3 which is essential for 
mast cell growth together with IL-4 and GM-CSF increase the expression of MHC 
class II on mast cells and allow them to induce T cell proliferation (Frandji et al., 
1993). 
Macrophages 
Macrophages are the major airway resident cells and participate in the maintenance 
lung immune homeostasis through phagocytosis and the release of mediators in 
response to antigens. However, their roles in asthma have not been well characterized. 
Lung macrophages are derived from circulating monocytes in the blood upon local 
attraction signals from chemokines (Barnes, 2004). Macrophages are known to be 




effective phagocytes and take up invading pathogens through the process of 
phagocytosis. Nonetheless, in the context of asthma, macrophages are appreciated as 
immune regulators. In mice, macrophages were reported to be negative regulators, 
modulating immune responses by inhibiting DC antigen presentation, T cell activation 
and antibody production (Bedoret et al., 2009). Similarly, a suppressive role of 
macrophages was shown in rats (Holt et al., 1993). Later on, the concept of 
alternatively activated macrophages (M2 cells), which express arginase 1, 
chitinase-like molecules and resistin-like molecule-α (FIZZ1), was proposed to 
describe macrophages that inhibit Th2 cytokine production by CD4 T cells (Nair et al., 
2009). Nevertheless, contrasting evidence was reported that under different stimuli, 
macrophages can produce both pro- and anti-inflammatory cytokines such as Th1 
cytokines, Th2 cytokines, IL-17 and IL-33 (Gordon, 2003). IL-33 (discussed below) 
was found to enhance the development of M2 cells, as Il33–/– mice display less 
OVA-induced airway inflammation associated with less M2 cell differentiation, and 
depletion of alveolar macrophages results in less IL-33-induced airway inflammation 
(Kurowska-Stolarska et al., 2009). A recent study demonstrated that the depletion of 
macrophages was able to alleviate prolonged AHR (Yang et al., 2010). As such, the 
regulatory roles of macrophages in vivo remain controversial, 
Neutrophils 
Profound neutrophil infiltration in the airway is more commonly observed in severe 
asthma with irreversible lung function impairment. It has been shown that 
inflammatory mediators such as myeloperoxidase, bactericidal/permeability 




increasing protein (BPI), defensins could be produced by activated neutrophils in 
severe asthma, contributing airway inflammation and remodelling (Bousquet et al., 
2000).  
1.5 Innate immune cytokines and asthma 
There is increasing evidence suggesting that innate immune mechanisms, involving 
an array of newly identified cytokines and target cells are able to elicit Th2 cytokine 
secretion, eosinophil recruitment and AHR. The availability of genetically modified 
mice which enable direct gene manipulation of these cytokines, has been the key in 
understanding the role of several innate molecules, cytokines and target cells (Kim et 
al., 2010).  
Thymic stromal lymphopoietin (TSLP)  
TSLP is an IL-7-like cytokine originally cloned from a mouse thymic stromal cell line. 
Studies on human primary epithelial cells have shown that TSLP could be released in 
response to microbial stimuli such as peptidoglycan, lipoteichoic acid and 
double-stranded RNA, physical injury, or inflammatory cytokines (such as IL-1β and 
tumor necrosis factor or TNF) (Allakhverdi et al., 2007). In asthmatic patients, TSLP 
expression is detected in the airways and TSLP mRNA expression correlates with 
disease severity (Ying et al., 2005). Correspondingly, up-regulation of TSLP mRNA 
expression has been found in the lungs of antigen-treated mice (Hammad et al., 2009). 
Consistent with this observation, TSLP receptor–deficient mice have considerably 
alleviated allergen-induced AHR (Zhou et al., 2005). It has been proposed that TSLP 
enhances Th2 inflammatory responses by activating DCs and up-regulating the 




expression of the ligand for co-stimulatory molecule OX40 on T cells. This is 
supported by the observation that in vivo blockade of OX40 ligand inhibits atopic 
inflammation driven by TSLP (Seshasayee et al., 2007), these findings suggest that 
airway epithelium-derived TSLP has an important role in the initiation of allergic and 
adaptive airway inflammation through innate pathways. 
IL-25  
IL-25, also known as IL-17E, is a newly-identified member of the IL-17 cytokine 
family. Both mouse and human lung epithelial lines have been found to express IL-25 
after exposure to allergens, particles and helminths (Hammad et al., 2009; Hurst et al., 
2002; Wang et al., 2007). Additionally, IL-25 is also produced by: activated 
eosinophils, bone marrow–derived mast cells, basophils after FcεRI crosslinking and 
by c-Kit+ cells after stimulation with stem cell factor (Dolgachev et al., 2009). 
Enhanced expression of IL-25 has been detected in the eosinophil-infiltrated bronchial 
sub-mucosal area of asthmatic patients, and elevated IL-17RB (IL-25 receptor) 
expression is also found in human primary lung fibroblasts (Letuve et al., 2006). In 
mouse models of asthma, several reports have shown that IL-25 amplifies Th2 
cytokine production and eosinophilia. In addition, OVA sensitization and challenge in 
wild type BALB/c mice results in increased IL-25 mRNA expression in the lung. 
Treatment with soluble IL-25 receptor fusion protein or antibody to IL-25 before 
OVA sensitization and challenge results in reduced AHR, airway inflammation and 
OVA-specific serum IgE (Ballantyne et al., 2007; Tamachi et al., 2006). Furthermore, 
a new type of innate immune cells has been found to be induced by IL-25, supported 




by the discovery that the administration of recombinant IL-25 induces production of 
IL-4, IL-5 and IL-13 in an innate non–B cell, non–T cell c-Kit+FcεRI– cell population 
that mediates rapid expulsion of helminths in both wild-type mice and 
recombination-activating gene-deficient (RAG−/−) mice (Fallon et al., 2006). Together 
these observations indicate that IL-25 acts on innate immune systems to amplify Th2 
immunity.  
IL-33  
IL-33 is a newly discovered member of the IL-1 family and has been detected in an 
array of cells (Liew et al., 2010). IL-33 acts in synergy with stem cell factor and the 
IgE receptor to activate primary human mast cells and basophils (Prussin and 
Metcalfe, 2006). IL-33 also enhances the survival of eosinophils and eosinophil 
degranulation in humans (Cherry et al., 2008). From mouse studies, enhanced IL-33 
production was detected in viral infection or following exposure to pathogen-derived 
products, irritants and even allergens (Hammad et al., 2009). In addition, OVA 
challenge induces the production of IL-33 protein in the lung, and IL-33 expression 
correlates with the maintenance of asthma (Kearley et al., 2009). When IL-33 is 
administered with OVA, IL-33 enhances airway inflammation in an IL-4-independent 
manner (Kurowska-Stolarska et al., 2009). Furthermore, the administration of IL-33 
can induce AHR and even enhance airway inflammation in ST2 (IL-33 receptor) 
-deficient mice (Hoshino et al., 1999; Kondo et al., 2008). Administration of 
neutralizing antibodies to IL-33 or ST2 attenuates eosinophilic airway inflammation 
and AHR (Coyle et al., 1999). Thus, IL-33 plays an important role in the development 




of asthma in mouse models, but the specific mechanisms by which IL-33 functions 
remains to be fully understood. 
IL-17  
IL-17 (also known as IL-17A) is one of the six members of the IL-17 family of 
cytokines (IL-17A–IL-17F). Naïve CD4 T cells can be differentiated into 
IL-17-producing T helper cells (Th17 cells) when conditioned by the combination of 
IL-6 and transforming growth factor-β (TGF- β) which induces the expression of 
RORγt, the lineage-specific transcription factor for Th17 cells and suppresses Foxp3, 
the lineage-specific transcription factor for regulatory T cells (Mangan et al., 2006). 
In addition to Th17 cells, γδ T cells (Lockhart et al., 2006), NKT cells (Caton et al., 
2007), neutrophils (Li et al., 2010) and macrophages (Song et al., 2008) produce 
IL-17, which is a potent neutrophil chemotactic agent. Notably, in asthmatic patients, 
the concentration of IL-17 in sputum correlates with the severity of AHR as well as 
the presence of neutrophils, which suggests an important role for IL-17 (Barczyk et al., 
2003). IL-17 or IL-17 receptor deficient mice show impaired Th2-type allergic airway 
inflammation, which suggests that IL-17A contributes to the development of this form 
of experimental asthma (Nakae et al., 2002). As endotoxin induces IL-17 production, 
it is possible that in this model, the induction of IL-17 enhances or facilitates the 
induction of Th2 responses. The same study also demonstrates that depleting alveolar 
macrophages or neutralizing IL-17 results in fewer inflammatory cells and lower 
concentrations of inflammatory factors in bronchoalveolar lavage (BAL) fluid. 




Together these studies suggest that IL-17A-secreting cells are important regulators of 
allergic asthma. 
1.6 Innate effector cells and asthma  
An innate lymphocyte which responds to both IL-25 and IL-33 has been identified in 
fat-associated lymphoid clusters (Moro et al., 2010) and in the mesenteric lymph 
nodes of helminth- infected mice (Neill et al., 2010; Saenz et al., 2010). Various 
names has been given to this newly-identified lymphocytes, such as “natural helper 
cells” (Moro et al., 2010), “neuocytes” (Neill et al., 2010), and “multipotent 
progenitor cells” (Saenz et al., 2010). Though their precise characteristics have yet to 
be fully described these innate lymphocytes are known to be lineage negative (ie do 
not express lineage marker such as Sca-1, IL-7R, IL-33R and IL-17RB), but are c-Kit 
positive. Being part of innate immune system, these cells can produce considerable 
amounts of Th2 cytokines when stimulated by IL-25 and IL-33. As they have high 
expression of MHC class II and costimulatory molecules, they may also act as APCs 
as well. It is particularly interesting that as multipotent progenitor cells, they can 
differentiate into the monocyte, macrophage, mast cell and granulocyte (eosinophil 
and basophil) lineages in the presence of stem cell factor and IL-3 in vitro (Saenz et 
al., 2010). Similarly, another non–B cell, non–T cell c-Kit+ FcεRI– cell population has 
identified, which produces large amounts of Th2 cytokines after IL-25 stimulation 
(Fallon et al., 2006; Fort et al., 2001). The fact that both IL-25 and IL-33 induce AHR 
without other stimulation suggests these natural helper cells might be one of several 




critical effector cells activated by IL-25 and IL-33, which mediate Th2-like responses 
in the lung, even in the absence of Th2 cells from adaptive immunity. 
Another important family of innate effector cells involved in asthma are natural killer 
T cells (NKT cells) with a unique feature of both classical T cells and NK cells. 
Particularly, invariant NKT cells (iNKT cells) express conserved or invariant T cell 
antigen receptors that function as an innate pattern recognition receptor (PRR) by 
recognizing both foreign and endogenous glycolipid antigens presented by the MHC 
class I–like molecule CD1d. After being stimulated, NKT cells produce large amounts 
of IL-4, IL-13 and IFN-γ, which have critical roles in the regulation of immune 
responses (Taniguchi et al., 2003). The iNKT cells are required for the development 
of AHR in several mouse models of asthma, as NKT cell–deficient mice (Cd1d–/– 
mice, which lack NKT cells, or mice deficient in α-chain joining region 18 (Jα18), 
which lack the invariant T cell antigen receptor), fail to develop AHR after allergen 
challenge (Akbari et al., 2003). Although the immunological pathways required for 
the development of AHR in these models of experimental asthma are distinct, with 
each requiring a phenotypically different NKT cell subset for the development of 
AHR(Matangkasombut et al., 2009), these observations suggest that many distinct 
pathways to asthma require the presence of NKT cells. Moreover, innate cytokines 
such as IL-25, TSLP and IL-33 can stimulate NKT cells to enhance AHR. 
IL-17RB-expressing iNKT cells are essential for the induction of AHR, as they 
produce IL-13 and Th2 chemokines after being stimulated with IL-25 (Stock et al., 
2009; Terashima et al., 2008). Wild-type mice depleted of IL-17RB+ NKT cells by 




IL-17RB-specific antibodies, as well as iNKT cell–deficient Jα18-deficient mice, fail 
to develop AHR after being stimulated with IL-25. In addition, adoptive transfer of 
IL-17RB+ iNKT cells into Jα18-deficient mice reconstitutes allergen-induced AHR. 
These studies suggest that IL-25 can exert some of its effects via NKT cells. Other 
data suggest that TSLP and IL-33 might also mediate some of their effects on AHR 
through iNKT cells (Bourgeois et al., 2009; Nagata et al., 2007; Smithgall et al., 2008) 
Together these observations indicate that iNKT cells seem to represent a common 
unifying element that is required for the development of AHR in several distinct 
models of asthma.  
iNKT cells have also been examined in BAL fluid, endobronchial biopsies and 
sputum samples from asthmatic patients. Although it has generated some controversy, 
the difference in the number of pulmonary iNKT cells in asthmatics in different 
studies can probably be accounted for by the heterogeneity of asthma (Akbari et al., 
2003). Patients with severe, poorly controlled asthma consistently had significantly 
more iNKT cells in BAL fluid, whereas patients with less severe disease were less 
likely to have more iNKT cells in BAL fluid (Edelson et al., 2010). Additionally, one 
study has demonstrated that allergen challenge of patients with asthma results in 
significantly more pulmonary iNKT cells associated with significantly more AHR, 
which suggests that iNKT cells have an important role in at least some forms of 
asthma. Nevertheless, functional studies in humans are needed to more fully assess 
the role of iNKT cells in human asthma.  
1.7 Dendritic cells  




As professional antigen presenting cells (APCs) dendritic cells (DCs) play a critical 
role in initiating adaptive immune responses by mediating the capture, processing and 
presentation of antigens to T cells (Steinman, 1991). The earliest identified DCs, were 
Langerhans cells that were found in the basal layer of the epidermis of the skin by 
Paul Langerhans in the mid-nineteenth century. However, they were thought to be 
neurons based on their dendrite structure. In the 1970s, the term ‘dendritic cells’ was 
coined by Ralph Steinmann to describe adherent cells with long dendrite extensions 
isolated from peripheral lymphoid organs, which were morphologically distinct from 
other mononuclear phagocytes (Steinman and Cohn, 1973). A seminal study by 
Steinman showed that DCs are critical accessory cells for the induction of primary 
mixed lymphocytes responses (Austyn et al., 1983). Naive T cell priming has been 
shown to be a unique feature of DCs which distinguishes them from other APCs such 
as B-cells and macrophages, probably due to their ability to express high levels of 
MHC class I and II as well as co-stimulatory molecules and long dendritic extensions 
which facilitate cell-cell interaction (Raue et al., 2004). Another important attribute 
for priming of CD4 T-cells, is their possession of specialised intracellular MHC Class 
II-rich compartments which facilitate peptide loading into MHC Class II molecules 
(Nijman et al., 1995). 
1.7.1 Origin of peripheral tissue DCs 
Precursors of DCs are derived from bone marrow hematopoietic stem cells and are 
seeded in various tissues through the circulatory system (Fogg et al., 2006; Onai et al., 
2007). Receptor tyrosine kinase kinase Flt3 is essential for the differentiation of DC 




precursors (Waskow et al., 2008). Terminal differentiation of DCs into different 
subsets is further regulated by key transcription factors which are unique to the 
development of that specific subset (Merad and Manz, 2009).  
The function of DCs changes with maturation. Immature DCs are functionally 
specialised for immune surveillance by actively acquiring antigen from the 
surrounding environment; hence monitoring for the presence of invading pathogens. 
When encountering with pathogens, DCs rapidly acquire a ‘mature’ phenotype 
wherein they down-regulate their antigen acquisition capacity and increase surface 
expression of MHC Class I or MHC Class II and co-stimulatory molecules such as 
CD40, CD80 and CD86 required for effective interaction with T cells (Banchereau et 
al., 2000). At the same time, DCs up-regulate the chemokine receptor CCR7 for 
homing to lymphoid tissues; thereby migrating from peripheral tissues to the draining 
lymph node to present the antigens to naive T cells (Gunn et al., 1999). 
1.7.2 Heterogeneity of peripheral tissue DCs 
As a heterogeneous population, DCs can be broadly categorised into those found in 
lymphoid and non-lymphoid organs. Within lymphoid organs such as the spleen and 
lymph nodes, there are three distinct DCs populations, namely CD4+CD8α-, 
CD4-CD8α+, and CD4-CD8α-, DCs (Vremec et al., 2000). Due to differences in 
expression of molecules involved in antigen processing machinery (Dudziak et al., 
2007) and antigen processing within intracellular compartments (Lin et al., 2008), 
different lymphoid DCs have distinct functions. It has been recognized that 




CD4+CD8α- DCs are highly specialised for CD4 T cell priming, whereas CD4-CD8α+ 
are more efficient at CD8 T cell cross-presentation.  
Heterogeneity of DCs in peripheral tissues is indicated by the variation of surface 
markers. Three DC subsets, namely CD11b+CD103+, CD11b-CD103+ and 
CD11b+CD103- DCs have been identified in small intestine, whereas in the lung only 
two subsets exist, which are the CD11b-CD103+ and CD11b+CD103- DCs (Edelson et 
al., 2010). Plasmacytoid DCs, which are non-classical DCs expressing the B-cell 
marker B220, are also present at many peripheral tissue sites, although at lower 
frequencies (GeurtsvanKessel et al., 2008).  
1.8 Lung dendritic cells  
Lung DCs were first described in 1986 as MHC Class II positive cells in the visceral 
pleura and other parts of the respiratory tract which shared structural similarities to 
Langerhans cells and possessed a distinct phenotype from alveolar macrophages and 
B-cells (Sertl et al., 1986). Characterization of murine lung DCs showed that they are 
potent stimulators of resting T cells in a primary allogeneic mixed leucocyte reaction 
(Pollard and Lipscomb, 1990). At steady state, lung DCs are widely disseminated and 
can be found in the tracheal epithelium, alveolar septal walls and conducting airways 
(Holt et al., 1988). Tracheal staining with MHC Class II reveals that airways are 
populated by numerous DCs with multiple long dendritic extensions.  
1.8.1 Lung DC subsets  
It has been thoroughly described that two main subsets of DCs exist in the lung, 
namely CD11b-CD103+ and CD11b+CD103- DCs (Sung et al., 2006). Imaging of the 




lung parenchyma reveals that both subsets are present in the periarteriolar region, 
however, CD11b-CD103+ DCs form the majority in the subepithelial region 
underneath the basal surface of bronchial epithelial cells. Although there is clear 
evidence that both lung DC subsets are derived from hematopoietic bone marrow 
progenitor cells, the specific precursors of these populations is unclear. Fate-mapping 
experiments using fluorescent latex beads injected into the blood of mice suggest that 
CD11b+CD103- DCs originate from Ly6ChiCCR2hi monocytes while CD11b-CD103+ 
DCs originate from Ly6CloCCR2lo monocytes (Jakubzick et al., 2008). Nonetheless, 
other groups argue that lung DCs do not derive from blood monocytes at all, but 
instead originate from pre-DCs, a rare DC progenitor cell population in the blood and 
bone marrow, which requires Flt3 for homeostatic differentiation into both CD11b+ 
and CD103+ DCs (Ginhoux et al., 2009).  
1.8.2 Lung DC function 
Lung DCs play a critical role as sentinels to monitor invading airborne pathogens in 
the lung, which is constantly exposed to the external environment. Constitutively, 
lung DCs sample antigens from the airway, migrate to the draining lymph node and 
present antigens to circulating lymphocytes. One study has demonstrated a rapid 
turn-over (2 days) of lung DCs in contrast to epidermal Langerhans cell’s (15-days) 
(Holt et al., 1994). This reflects a continual and rapid replenishment of DCs in the 
lung to take the place of those that have migrated to the lymph node. A subsequent 
studies showed that upon encounter with pathogens or TLR stimulus, lung DCs can be 




rapidly mobilised and display an accelerated migration rate to the lymph node within 
24 hours of challenge (Legge and Braciale, 2003). 
Lung DCs play a critical role in discriminating airborne pathogens from innocuous 
environmental antigens that challenge the lung (de Heer et al., 2004; Hurst et al., 2001; 
Van Hove et al., 2007). Unsuccessful activation of lung DCs upon encounter with 
harmless inhaled antigens is one possible explanation for the ability of lung DCs to 
induce tolerance (Sousa, 2006; Sporri and Reis e Sousa, 2005). Immature or partially 
mature DCs can direct the development of IL-10 secreting CD4 T-regulatory T cells 
in an IL-10 and ICOS-dependent manner (Akbari et al., 2001; Akbari et al., 2002). In 
addition, it has been demonstrated that the ability of lung DCs to migrate to draining 
lymph nodes is also critical for the induction of tolerance (Hintzen et al., 2006).  
The presence of danger signal from invading pathogens can break lung tolerance via 
lung DCs. PRRs expressed by innate immune cells that recognize PAMPs trigger 
adaptive immunity (Akira et al., 2006). Dendritic cells are known to express a wide 
repertoire of PRRs including toll-like receptors (TLR), nod-like receptors (NLR) and 
RIG I-like receptors (RIR). The expression of these receptors on lung DCs is critical 
for establishing tolerance to inhaled antigens as maturation of lung DCs induced by 
TLR stimulation (Eisenbarth et al., 2002) or infection with influenza (Brimnes et al., 
2003).  
1.8.3 Lung DCs in asthma 
As key players in the pathogenesis of asthma, CD4 T cells, particularly Th2 cells 
produce cytokines that regulate the allergen-specific synthesis IgE through IL-4, the 




recruitment of eosinophils through IL-5 and AHR, a cardinal feature of asthma IL-13. 
Although Th2 CD4 T cells are responsible for facilitating the pathophysiological 
development of asthma, it is increasingly recognised that lung DCs also play a critical 
by orchestrating the priming and polarization of CD4 T cells (Hammad et al., 2007; 
Hammad et al., 2010; van Rijt et al., 2005a).  
Lung resident DCs potent inducers of adaptive immune responses through their ability 
to capture inhaled allergens at the lung surface and migrate to the T cell area of 
draining mediastinal lymph nodes to prime and polarize allergen-specific CD4 T cells 
(Kapsenberg, 2003). Lung DCs control sensitisation to allergens and are gatekeepers 
of immune responses that ultimately result in the development of asthma. The 
adoptive transfer of OVA-pulsed DCs into the lungs can induce Th2 responses against 
OVA (Lambrecht et al., 2000). Similarly, depletion of lung DCs prior to intranasal 
challenge using the CD11c-DTR mice model was accompanied by the loss of the 
characteristic features of asthma (van Rijt et al., 2005a), demonstrating that lung DCs 
are indeed central to the induction of allergic responses. 
Despite the overwhelming evidence for its indispensable role for induction of Th2 
immunity, DCs were never found to produce IL-4 which is required to activate 
transcription factors STAT6 and GATA-3, thereby driving Th2 cell differentiation. It 
has been suggested that basophils and not lung DCs serve as an early source of IL-4 
for skewing of type II responses (Sokol et al., 2009). This conclusion was later shown 
to be incorrect as the use of anti-FcεRI to deplete basophils also resulted in 
concomitant depletion of a subset of inflammatory DCs which also expressed FcεRI. 




Furthermore, when more stringent protocols were applied for cell purification and 
analysis, basophils poorly acquired fluorescent antigen in the lung, did not express 
high levels of MHC II, poorly stimulated CD4 T cell proliferation and did not induce 
sensitisation to allergen when adoptively transferred intratracheally (Hammad et al., 
2010). 
It has been shown that pulmonary immune tolerance rather than airway inflammation 
can be induced by respiratory administration of a harmless antigen OVA via 
IL-10-producing lung dendritic cells (Akbari et al., 2001). However, the presences of 
a “danger” signal such as lipopolysaccharide (LPS) within OVA antigen is sufficient 
to break tolerance by simulating the TLR4 pathway on lung DCs (Eisenbarth et al., 
2002). By contrast, inhalant allergens induce allergic asthma. For instance, 
development of Th2 responses to inhaled house dust mite (Der p) have been found to 
depend on the protease activity of its major allergen Der p 1 via enzymatic cleavage 
of CD25 expressed on B cells and tight junction between lung epithelial cells 
(Chapman et al., 2007; Gough et al., 1999). More interestingly, a seminal study 
reported that the allergenicity of Der p resulted from its functional mimicry of MD2, a 
toll-like receptor 4 complex protein by acting as an intrinsic auto-adjuvant (Trompette 
et al., 2009).  
There is increasing evidence that lung DCs do not act in isolation but instead rely on 
instructions from bronchial epithelial cells which first attract DCs via release of 
chemokines and skew DC function towards a Th2 activating mode by secreting pro- 
Th2 cytokines such as TSLP, IL-25 and IL-33 (Lambrecht and Hammad, 2010). 




Further support for this hypothesis comes from the observation that overexpression of 
these cytokines (which are not DC derived), results in spontaneous Th2 sensitisation 
to harmless proteins (Zhou et al., 2005). 
Although the lung DCs have been shown to control the induction of allergic responses 
to dust mite (Lambrecht and Hammad, 2009), it is unclear which lung DC subset is 
responsible for priming Th2 CD4 T cells. The relative contribution of each DC subset 
to the pathogenesis of dust mite allergy is not clear, as studies using ex vivo sorted 
lung DCs have led to conflicting reports about the contribution of CD103+ and 
CD11b+ DCs to Th2 priming (Furuhashi et al., 2012; Mesnil et al., 2012; Nakano et 
al., 2012; Plantinga et al., 2013). In addition, although mouse models exist which 
permit the selective depletion of lung CD103+ DCs (GeurtsvanKessel et al., 2008), 
thus far there have been no models to specifically deplete resident lung CD11b+ DCs. 
This is likely due to the heterogeneity of mouse CD11b+ DC compartment, as 
suggested by their partial dependence on CSF-1R (Colony stimulating factor 1 
receptor) and Flt3 (Ginhoux et al., 2009). 
1.8.4 Epithelial cells and DCs 
Epithelial cells are the first line of defence when foreign substances enter into the 
airway. In recent years, increasing evidence has suggested an underappreciated role of 
epithelial cells in asthma responses (Prefontaine and Hamid, 2007). The role of 
epithelial cells in orchestrating allergic inflammation is closely related to DCs 
(Lambrecht and Hammad, 2010).  




It has been shown that epithelial integrity, namely tight junction between epithelial 
cells could be disrupted by allergen possessing protease activity (Chapman et al., 
2007). Upon exposure to foreign allergens, epithelial cells produce various 
chemokines and cytokines which affect DC recruitment and activation (Hammad and 
Lambrecht, 2008). For instance, thymic stromal lymphopoietin (TSLP), derived from 
lung epithelium, has been shown to bind to its receptor complex on DCs and in turn 
trigger up-regulation of the co-stimulatory molecule OX-40L on DCs (Ito et al., 2005). 
Mice that over-express TSLP have been reported to display a vigorous Th2 response 
in the lung upon innocuous antigen exposure, whereas TLSP knockout mice fail to 
develop antigen-specific Th2 response in the airways (Al-Shami et al., 2005; Zhou et 
al., 2005).  
1.9 Adaptive immune system in asthma  
As opposed to innate immunity, the adaptive immune system comes into play at a 
later stage after exposure to antigen and acts in an antigen-specific manner. Eliciting 
adaptive immunity is highly dependent on the innate response, but once 
antigen-specific memory cells are generated, strong and long-lasting immune 
responses can confer protection against invading pathogens upon secondary exposure. 
Although the adaptive immunity is known to be critical to clear viral infection and 
cancerous tumour cells, it is nevertheless a key player in the pathogenesis of asthma. 
Adaptive immunity in asthma is centred by two major components, namely 
IgE-secreting B cells and Th2 CD 4 T cells. Nonetheless, CD8 cells and other types of 




CD 4 T cell such as Th1, Th2 and regulatory T cells are also being suggested to play a 
role in regulating asthma responses.  
1.9.1 B cells in asthma  
Immature B cells originate from bone marrow hematopoietic stem cells and migrate 
into lymphoid tissues with IgM expressed on the surface. Immature B cells continue 
to develop with progressive changes in the isotypes of antibody expressed. Upon 
antigen exposure, B cells undergo affinity maturation and isotype switch, which is 
assisted by follicular dendritic cells and CD4 T cells (Vale and Schroeder, 2010). 
In the context of asthma, with the help of CD4 T cells for isotype switching, B cells 
mainly produce IgE, an important mediator in the pathogenesis of asthma (Fahy, 
2006). The basal level of IgE is able to prime mast cells and basophils by binding to 
high affinity FcεRI expressed on their surface. Upon allergen exposure, antigen-IgE 
crosslinking on the surface of mast cells and basophils leads to degranulation resulting 
in the release of various inflammatory mediators which in drive the early phases of 
allergic reactions. In addition, activated mast cells and basophils also produce an array 
of cytokines and chemokines that are responsible for the initiation of late phase 
allergic reactions (Gould and Sutton, 2008). Lung stromal cells such as epithelial cells 
and smooth muscle cells may also participate in the pathogenesis of asthma through 
FcεRI (Fahy, 2006). 
1.9.2 Th2 cells in asthma  
CD4 T cells differentiate into Th2 cells under the control of the transcription factor 
Trans-acting T-cell-specific transcription factor 3 (GATA-3) (Ouyang et al., 1998; 




Zhang et al., 1997). Th2 cells have been characterized by their capacity to produce 
Th2 cytokines such as IL-4, IL-5, IL-10 and IL-13. Increased number of Th2 cells 
were observed in the early 1990s in asthmatic patients and hence asthma was defined 
as a Th2-mediated disease (Bentley et al., 1992; Robinson et al., 1992). It is well 
established that Th2 cells are critical in the pathogenesis of asthma (Cohn et al., 2004) 
and the number of Th2 cells in the airway positively correlates with the severity of 
asthma (Larché et al., 2003). 
Specific cytokines are responsible for different aspects of asthmatic disease 
manifestation. IL-4, for example, is important in Th2 differentiation and B cell isotype 
switching to IgE (Finkelman et al., 2010b). IL-4-deficient mice fail to develop allergic 
inflammatory responses due to defective Th2 priming (Brusselle et al., 1994) while 
blockage of IL-4 during the challenge phase did not affect the establishment of 
inflammation (Coyle et al., 1995), further proving that IL-4 is principally required 
during. IL-5 and IL-13 on the other hand, are mainly involved during the elicitation 
phase of allergic responses. More specifically, IL-5 is crucial for the survival and 
migration of eosinophils while IL-13 plays a more complicated role. Other than the so 
called redundant role that IL-13 plays in the isotype switch of B cells, IL-13 is also 
important in the development of AHR, mucus secretion and airway remodeling 
(Finkelman et al., 2010a). 
1.9.3 Th1 cells in asthma 
Th1 cells are characterized as CD4 T cells which produce Th1 cytokine interferon 
gamma (IFN-γ) and its differentiation is mainly governed by T box transcription 




factor T-bet and IL-12 (Athie-Morales et al., 2004; Szabo et al., 2000). Typical Th1 
response are generated in infectious disease such as influenza infection wherein they 
play a major in regulating CD8 cells mediated anti-viral clearance. It has been 
suggested that Th1 and Th2 cells are in balance by suppressing the differentiation and 
activation of each other; therefore, Th1 cells may regulate asthma by exerting an 
inhibitory effect on Th2 cells (Abbas et al., 1996). Reduced exposure to mycobacteria 
and virus infection could lead to uncontrolled Th2 immunity and increased incidence 
of allergic asthma (Shirakawa et al., 1997; von Hertzen et al., 1999) and led to the 
development of hygiene theory in which a failure to activate Th1 immunity resulted 
from insufficient exposure to environmental bacterial or viral infection and enhanced 
Th2 responses. Nonetheless, mice that were adoptively transferred with Th1 cells 
have been shown to display unchanged AHR induced by Th2 cells, although 
eosinophil infiltration in the airway is suppressed (Hansen et al., 1999). Moreover, 
additional studies demonstrated that antigen-specific Th1 cell transfer even enhanced 
eosinophilia in murine model of asthma (Li et al., 1998; Randolph et al., 1999). In 
addition, there is evidence showing that although enhanced IFN-γ production due to 
Th1 immunity or IL-4/Th2 deficiency could limit inflammatory responses by 
preventing egression of eosinophils, it could not yield a satisfactory therapeutic result 
altogether (Boguniewicz et al., 1995; Cohn et al., 2001). In brief, the role of Th1 in 
asthma remains to be further defined. 
1.9.4 Th17 cells in asthma 




As a new family member in CD4 T cell subsets, Th17 cells are identified by the 
expression of transcription factor retinoid acid receptor-related orphan 
receptor-gamma t (RORγt) and the production of IL-17A (Harrington et al., 2005; 
Park et al., 2005). Th1 differentiation is governed by IL-12 and Th2 is instructed by 
IL-4; likewise, Th17 cells has its own directing cytokine which is transforming 
growth factor β (TGF-β) and IL-6 with IL-23 (Al-Ramli et al., 2009; Mangan et al., 
2006). However, it is still not clear which cytokines are involved in human Th17 
development (Alcorn et al., 2010). Some studies have shown that Th17 cells are 
responsible for the infiltration of neutrophils and are also involved in acute AHR (He 
et al., 2007; Wilson et al., 2009). IL-17A, one isoform of IL-17, has been found to be 
up-regulated in the lungs of asthmatic patients and the level of which correlates with 
the severity of asthma, especially in patients with neutrophilic and steroid-resistant 
asthma (Al-Ramli et al., 2009; Molet et al., 2001). Additionally, lung infiltrating 
IL-17+ CD4 T cells have been found in asthmatic patients (Pene et al., 2008). 
Employing IL-23 neutralization, or creating mice with IL-23 over-expression provides 
evidence that Th17 cells could exacerbate Th2 cell-mediated airway eosinophilic 
inflammation; adoptive transfer of Th17 cells showed Th17 cells promoted 
steroid-resistant airway inflammation and AHR (McKinley et al., 2008; Wakashin et 
al., 2008). Taken together, Th17 cells and the cytokines they produce are closely 
related to asthma pathogenesis and may yield promising therapeutic effect in severe 
and steroid-resistant asthma. 
1.7.5 Regulatory T cells in asthma  




Regulatory T cells are particularly relevant in pulmonary immune tolerance 
(Hawrylowicz and O'Garra, 2005; Holt et al., 2008; Lloyd and Hawrylowicz, 2009). 
As discussed earlier, immature or partially mature DCs can lead the development of 
IL-10 secreting CD4 T-regulatory T cells in an IL-10 and ICOS-dependent manner 
(Akbari et al., 2001; Akbari et al., 2002). These IL-10-producing CD4 T cells are one 
of many types of regulatory T cells that have been characterized. Additionally, 
CD4+CD25+ T cells, which express the transcription factor forkhead box 3 (Foxp3) 
and produce IL-10 and TGF-β, have been recognized for their suppressive effects on 
the proliferation and function of effector T cells and thus regulation of disease 
progression (Ray et al., 2010). Adoptive transfer of this kind of regulatory T cells was 
shown to suppress allergic inflammation and AHR via IL-10-dependent mechanisms 
(Kearley et al., 2005). Even when transferred after the onset of the disease, these cells 
were still able to attenuate established inflammation and suppress airway remodeling 
(Kearley et al., 2008). The role of regulatory T cells has been extensively investigated 
in depletion studies (Lewkowich et al., 2005). It has been shown that regulatory T 
cell-depletion leads to enhanced inflammation and AHR and its inhibitory effect has 
been suggested to associate with decreased activation and antigen presentation 
capacity of dendritic cells. 
1.9.5 CD8 T cells in asthma 
Unlike CD4 T cells which confer their regulatory effects in different diseases and 
conditions, CD8 T cells exert profound immune function mainly in viral infections 
and cancer. Nevertheless, the concept that CD8 T cell may play a regulatory role in 




asthma was proposed and studies showed that CD8 T cells could inhibit allergic 
sensitization to OVA represented by IgE (Diaz-Sanchez et al., 1993; Okumura et al., 
1977; Sedgwick and Holt, 1984; Tada et al., 1972). Later, CD8 T cells were also 
shown to attenuate Th2 responses in the airway (Ishimitsu et al., 2001; Renz et al., 
1994; Wells et al., 2007a). However, it became apparent that there are different 
subsets of CD8 T cells when several subsequent studies showed that in contrast to 
their suppressor activity, CD8 T cells could also contribute to allergic responses 
(Hamelmann et al., 1996; Holmes et al., 1996; Miyahara et al., 2004). In short, the 
role of CD8 T cells in asthma has yet to be defined.  
1.10 Aims of the study 
Dendritic cells (DCs) are essential for the initiation and maintenance of allergic 
immune responses. Lung resident DCs are subdivided into functionally distinctive 
subsets, namely the CD103+ DCs and CD11b+ DCs, but it is unclear which one is 
responsible for priming Th2 CD4 T cells. GM-CSF is crucial for the development of 
allergic asthma as blockade of GM-CSF abrogates the development of Th2 responses. 
However, little is known about how GM-CSF potentiates Th2 priming and whether 
this effect is mediated through the licensing of lung DCs. In this study, we sought to 
investigate the role of lung resident DCs in a novel murine asthma model induced by 
dust mite Blomia tropicalis (Blo t), a major asthma allergen in the tropics, and to 
examine the contribution of GM-CSF in potentiating the asthmatic response through 
lung DCs. 
Specific objectives:  




1. Establish a novel murine asthma model induced by dust mite Blo t 
2. Investigate the role of lung resident DCs in the murine asthma model induced 
by Blo t 
3. Study the contribution of GM-CSF to promoting asthma through lung DCs
  
 




CHAPTER 2: Materials and Methods 
 
2.1 Media and buffers 
 
PBS buffer 
PBS buffer was purchased from 1st base (Singapore) as an ultrapure grade 10 × stock. 
It consists of 137mM NaCl, 2,7mM KCI and 10mM phosphate buffer. 1× PBS buffer 
was yielded by diluting filtered 10 × stock with 9 parts of sterile and filtered water. 
pH was adjusted to 7.2-7.4 by pH meter.  
 
MACS buffer 
MACS buffer consists of 1× sterile PBS supplemented with 5mM filtered and sterile 
EDTA (1st base, Singapore) and 2% FCS (Biowest, USA). pH was adjusted to 7.2-7.4. 
 
FACS buffer 
FACS buffer consists of 1× sterile PBS supplemented with 5mM filtered and sterile 
EDTA and 2% FCS. 0.05% sodium azide was added as a preservative to permit use 
and storage under non-sterile conditions. pH was adjusted to 7.2-7.4.  
Important note: Although it has similar components as MACS buffer, FACS buffer is 
not suitable for isolating cells and related cell culture procedures. Although not toxic 
to the cells at the concentration used, sodium azide may exert potential inhibitory 
effect on the metabolic functions of the cells. 






Cell permeabilization buffer consists of 1× sterile PBS supplemented with 0.1% BSA, 
0.1% Saponin and 0.1% sodium azide. pH was adjusted to 7.2-7.4. Alternatively, 
commercially available permeabilization/fixation and permeabilization/washing 
buffer were purchased from BD biosciences, Singapore.  
 
Red Blood Cell Lysis buffer 
1. To make a 10 × RBC lysis buffer stock, 82.9g Ammonium chloride, 10g 
sodium bicarbonate and 2ml 0.5M EDTA were added into 1L Schott bottle.  
2. Make up to 1 L by diluting and adding sterile and deionized water. Magnetic 
stirrer was used to facilitate dissolution. pH was adjusted to 7.2-7.4.  
3. 1× RBC lysis buffer was yielded by diluting 10 × stock with sterile and 
deionized water.  
 
Optiprep density centrifugation media for dendritic cell isolation  
Optiprep (Sigma, Singapore) was provided as 60% w/v Iodixanol in water with a 
density of 1.32g/ml that has been tested for endotoxin (less than 0.13EU/ml). 
Optiprep was diluted using Optiprep diluent (see formula below) to 11.173 % w.v 
(5.515 × dilution with Optiprep diluent) with a density of 1.062g/ml.  
Calculation of required density: y =0.00052 x + 1.0054 (where y = g/ml <density>, x 
= % w/v) 




Optiprep diluent: 0.8% (w/v) NaCl, 5mM EDTA, 10mM Tricine NaOH, pH=7.4 
(prepared under sterile condition) 
 













18.62 81.38 100 
37.24 162.76 200 
55.87 244.13 300 
74.49 325.51 400 
93.11 406.89 500 
 Liberase Digestion Blend 
Liberase TL Research Grade (low thermolysin concentration) was purchased from 
Roche (Roche Applied Science, USA) and dissolved in plain RPMI-1640 to obtain a 
10 × stock solution with a concentration of 2mg/ml which was further liquated and 
stored at -30°C. For tissue digestion, 10 × stock solution was diluted 10-fold with 
plain RPMI-1640, supplemented with 1% v/v FCS, which was added to preserve the 
viability of DCs.  
 
Buffers for ELISA 
Wash buffer: 1 × PBS with 0.5% v/v Tween-20 (pH = 7.2-7.4) 




Blocking buffer (Assay Diluent): 1 × PBS with 1% w/v BSA 
Stop Solution: 2N H2SO4 
 
Complete RPMI for cell culture 
Complete RPMI was prepared using RPMI-1640 with L-Glutamine (Invitrogen, 
Singapore) with the following supplements:  
1. 10% v/v FCS which had been heat-inactivated at 55°C for 30 mins 
2. 1% v/v Non-essential amino acid (Sigma, Singapore) from 100 × stock 
3. 1mM Sodium Pyruvate (Sigma, Singapore) 
4. 50µM β-Mercaptoethanol (Sigma, Singapore) 
5. 100IU/ml Penicillin and 0.1 mg/ml Streptomycin (Sigma, Singapore) 
 
Paraformaldehyde (4%) 
Beware of its toxicity, weigh paraformaldehyde power (Sigma, Singapore) in a fume 
hood to avoid inhaling the particulate matter. Mask is recommended. Prepare a 4% 
paraformaldehyde solution with 1× PBS (w/v). Incubate the solution in water batch at 
60°C for approximately 40 minutes to fully dissolve paraformaldehyde in PBS. As 
paraformaldehyde will settle at the bottom of the falcon tube, it is necessary to 
re-suspend the solution every 10 minutes or so. 
 
2.2 Mice 




Age- and sex-matched 8-10 week old C57BL/6 and BALB/c mice were purchased from 
the animal breeding center of the National University of Singapore. DO11.10 mice, 
4get mice, CCR2 knockout mice and CD11c-Cre mice were purchased from the 
Jackson Laboratory (Maine, USA). Langerin-eGFP-DTR mice were provided by 
Bernard Malissen and IRF4-flox mice are from Ginhoux lab. 4get x DO11.10 mice 
were generated by crossing homozygous 4get mice with homozygous DO11.10 mice. 
All experiments were conducted in accordance with institutional guidelines of the 
National University of Singapore and Biopolis Resource Centre Institutional Animal 
Care and Use Committees under protocol numbers 029/09 and 090444. 
• DO11.10 mice: knock-in mice (BALB/c background) carrying the MHC class 
II restricted rearranged T cell receptor transgene, Tg (DO11.10)10Dlo, react to 
ovalbumin (OVA) peptide antigen (OVA323-339 peptide) (Murphy et al., 
1990). 
• 4get mice: knock-in mice (BALB/c background) homozygous for 
“IL-4/GFP-enhanced transcript” (4get). A knock in replaces endogenous gene 
with an IL-4/IRES/eGPF gene (while IL-4 activity remains intact). This leads to 
generation of a bicistronic transcript under the control of endogenous regulatory 
elements. Cells activated to express IL-4 will express eGPF simultaneously, 
which allows reliable in vivo tracking of IL-4 producing innate and adaptive 
immune cells and enables their isolation without further stimulation. As the 
(Internal Ribosome Entry Site)IRES element promotes translational 
competence capable of revealing low-level transcription otherwise not apparent 




from the canonical 5’-cap of the mRNA, cells isolated from 4get mice can also 
be used to report the competence of IL-4 production upon stimulation (Mohrs et 
al., 2001). 
• CCR2 knockout mice: knock-out mice (C57BL/6 background) homozygous 
for CCR2 chemokine receptor targeted mutation (Boring et al., 1997). 
• CD11c-Cre mice: knock-in mice (C57BL/6 background) hemizygous for 
CD11c-Cre transgene. These transgenic mice express Cre recombinase under 
the control of the mouse integrin alpha X (CD11c) promoter. When bred with 
any mouse containing a loxP-flanked sequence of interest, the resulting 
offspring can have Cre-mediated recombination of the flanked sequence. 
Therefore, these CD11c-Cre transgenic mice are useful for immunological 
studies utilizing Cre-lox technology or fluorescent protein expression in 
dendritic cells (Jung et al., 2002).  
• Langerin-eGFP-DTR mice: knock-in mice (C57BL/6 background) expressing 
eGFP fused with a diphtheria toxin (DT) receptor (DTR), under the control of 
the Langerin promoter. Administration of DT leads in 24 hr to the elimination 
of all Langerin+ cells, without affecting the Langerin− DC compartment 
(Kissenpfennig et al., 2005). 
• IRF4-flox mice: mice (C57BL/6 background) wherein exon 1 and 2 of the 
IRF4 gene are flanked by loxP sites (IRF4flox/flox). When IRF4-flox mice 
were crossed with CD11c-Cre mice, expression of the Cre recombinase leads to 




excision of both exons, preventing transcription of the IRF4 gene only in 
CD11c+ compartment (Klein et al., 2006).  
 
2.3 Cell isolation 
 
2.3.1 Isolation of CD4 T cells by magnetic separation 
 
1. Spleens and lymph nodes were harvested from mice and physically disrupted 
by pushing through a 70µm cell strainer to obtain a single cell suspension.  
2. Cells were washed once in MACS buffer and layered onto Ficoll-Paque (GE 
Healthcare, USA) and centrifuged at 600 × g for 20 minutes (with zero 
acceleration/brake) at room temperature.  
3. Cells that accumulated at the interface were collected, washed with MACS 
buffer and counted.  
4. Cells were pelleted and raked to single cell suspension. Anti-CD4 microbeads 
(Miltenyi Biotec, Singapore) were added into the suspension at 4µl per million 
cells.  
5. The cells were further incubated in the dark at 4°C for 30 minutes with 
occasional flicking of the tube every 10 minutes to prevent cell settle at the 
bottom of the tube.  
6. After incubation, cells were washed with MACS buffer, spun down, 
re-suspend in 1ml MACS buffer and further loaded onto LS column (Miltenyi 
Biotec, Singapore) which has been pre-equilibrated with MACS buffer. 




7. The column was washed with MACS buffer for 3 times before eluting with 
2ml complete RPMI. 
2.3.2 Adoptive transfer of CD4 T cells 
1. CD4 T cells which have been enriched by magnetic separation as described 
earlier were washed with PBS buffer for three times. 
2. Re-suspend the cells in PBS buffer at a concentration of 25 million per ml. 
3. Restrain the recipient mice in mouse restrainer after applying lidocaine to 
dilate their tail vein with sufficient heating from heating lamp. 
4. Transfer 2.5 million cells (100µl) into recipient mice through intra-venous 
injection.  
2.3.3 Sorting of CD4 T cells 
1. After initial enrichment by magnetic separation as described earlier, cells were 
washed with MACS buffer and spun down. Fc Block (2.4G2) was added at 
0.2µg per million cells and cells were incubated for 5 minutes at 4°C to 
prevent non-specific binding of antibodies to Fc receptors.  
2. Subsequently, fluorophore directly conjugated antibodies CD4-PB (RM4-5; 
BD Pharmingen), CD11c-PerCPCy5.5 (N418; eBioscience), 
CD19-PerCPCy5.5 (145-2C11; eBioscience), CD62L-FITC (MEL-14; 
Biolegend), CD44-APC (IM7; BD Pharmingen) and CD25-PE (PC61; 
Biolegend) were added at 0.02µg per million cells and cells were incubated in 
the dark at 4°C for another 30 minutes.  




3. After incubation, cells were washed with MACS buffer, spun down, 
re-suspended in 2ml MACS buffer and further passed through a 61µm strainer 
to filter out cell clumps or any tissue pieces which may clog the cell sorter.  
4. The filtered cells were then pelleted one more time. Finally, cells were 
re-suspended to a concentration of 20-25 million cells/ml and CD4 T cells 
were sorted using MoFlo (Beckman Coulter, USA). 
5. Sorted CD4 T cells were collected in sterile FACS tubes containing neat FCS. 
2.3.4 CFSE labeling of CD4 T cells 
1. Re-suspend the cells sorted by flow cytometry at a concentration of 1 million 
cells/ml. 
2. Add 2µl of 5mM stock CFSE solution per milliter of cells for a final working 
concentration of 10µM.  
3. Incubate the cells at 37°C for 20 minutes, protected from light. 
4. Quench the staining by the addition of 5 volumes of complete RPMI to the 
cells and incubate for 5 minutes. This step removes any free dye remaining in 
the solution. 
5. Pellet cells by centrifugation and re-suspend them in fresh, pre-warmed 
complete RPMI. 
2.3.5 Isolation of dendritic cells from lung Parenchymal  
1. Lungs were harvested from sacrificed mice and collected into 1 × Liberase 
digestion blend. The lungs were finely cut by scissors and incubated at 37°C 
for 15 minutes. The partially digested lungs was re-suspended with a Pasteur 




pipette to break it into smaller pieces and further incubated for another 15 
minutes.  
2. The resulting digested cells were then pushed through a 70µm cell strainer 
(BD Pharmingen, USA) to obtain a single cell suspension. The cells were 
washed twice in MACS buffer to remove any trace of digestion blend. 
3. After pelleting, cells were vigorously raked and re-suspended in 3ml of 
Optiprep (g=1.064g/ml). 2ml of FCS was gently layered onto the Optiprep cell 
solution. The cells were spun at 1700 × g for 10 minutes at 4°C (with zero 
acceleration/brake).  
4. Cells that accumulated at the interface between Optiprep and FCS were 
harvested and washed with MACS buffer.  
5. Cells were spun down to obtain cell pellet which was raked to re-suspend cells 
and anti-CD11c microbeads were added at a 10µl per 10 million cells with a 
minimum of 10µl of beads being used. The mixture was incubated at 4°C for 
10 minutes. 
6. Cells were washed with MACS buffer and spun down after incubation. 
Re-suspend the cells in 1ml MACS buffer before being applied into LS MACS 
column which has been pre-equilibrated with MACS buffer. 
7. The column was washed with MACS buffer for 3 times before eluting with 
2ml complete RPMI. 
8. After initial isolation by magnetic separation, cells were washed with MACS 
buffer and spun down. Fc Block (2.4G2) was added at 0.2µg per million cells 




and cells were incubated for 5 minutes at 4°C to prevent non-specific binding 
of antibodies to Fc receptors.  
9. Subsequently, fluorophore directly conjugated antibodies CD103-APC (2E7; 
eBioscience), I-A/I-E-V500 (M5/1114.15.2; BD horizon), CD11c-PerCPCy5.5 
(N418; Biolegend), CD24-eFluor450 (M1/69; eBioscience); CD64-PE 
(X5-5/7.1; Biolegend), CD11b-PE-Cy7 (M1/70; eBioscience) were added at 
0.02µg per million cells and cells were incubated in the dark at 4°C for 
another 30 minutes.  
10. After incubation, cells were washed with MACS buffer, spun down, 
re-suspended in 2ml MACS buffer and further passed through a 61µm strainer 
to filter out cell clumps or any tissue pieces which may clog the cell sorter.  
11. The filtered cells were then pelleted one more time. Finally, cells were 
re-suspended to a concentration of 20-25 million cells/ml and CD4 T cells 
were sorted using MoFlo. 
12. Sorted DCs were collected in sterile FACS tubes containing neat FCS. 
2.3.6 Sorting of dendritic cells from lung draining lymph node  
The protocol for sorting DCs from draining lymph node (mediastinal lymph node) is 
almost identical to that for sorting DCs from lung parenchymal, with the exception 
that Optiprep density centrifugation and magnetic separation were not performed, to 
minimize cell lose during the process. After digestion, cells were directly stained with 
conjugated antibodies and sent for cell sorting. 
 




2.4 Asthma model: sensitization and airway challenges  
 
2.4.1 Allergen extraction  
Ten grams of frozen Blomia tropicalis, Siriraj Dust Mite Center (Bangkok, Thailand) 
were extracted overnight with slow stirring at 4°C in 1× PBS, centrifuged at 13000g for 
30 min at 4°C, filtered through a 0.22 μm filter and stored at -80°C. 
Important note: Total protein concentration was determined by Bradford Assay 
(Bio-Rad, Singapore) and endotoxin was measured by LAL Assay (Lonza, Singapore). 
Throughout the whole study, we used Blo t extracts with high protein concentration and 
low endotoxin level (<10EU/mg) to minimize protein degradation during experimental 
procedures and cellular/molecular effect brought by endotoxin contamination.  
2.4.2 Precipitation of Blo t-alum 
 
1. Add 0.45ml of 1M NaHCO3 in sterile distilled water to 1ml of Blo t extracts at 
room temperature and gently mix. 
2. Add 1ml of 0.2M KAl (SO4)2.12H20 in sterile distilled water (preferably 
freshly prepared) drop-wise to the mixture while stirring. Maintain the mixture 
at 25°C for 20 minutes and then centrifuge at 3000g for 10 minutes.  
3. Wash the precipitate three times in sterile PBS. 
4. After the last wash, discard supernatant and re-suspend the cell pellet in 10ml 
of sterile PBS. 
5. Store alum-antigen mixture at 4°C for up to 24 hours. 
6. Dilute the 1mg/ml Blo t-alum mixture 1:10 prior to injection.  
2.4.3 Sensitization and challenge protocol (intraperitoneal sensitization) 





1. At day zero, inject 100µl of 1mg/ml Blo t-alum intraperitoneally (i.p.), 
resulting in 100µg per mouse. 
2. At day 14, inject another 100µg per mouse as a booster. 
3. The intranasal challenges take place at days 21, 22, 23. Connect isofluorane 
machine to the isofluorane chamber within the Biosafety Cabinet. Open 
oxygen tap, set isofluorane dial to level 4 and turn on isofluorane flow. After 
one minute or so, transfer the mice into the chamber and wait until they are 
completely knocked out, indicated by a steady yet shallow breathing. 
4. Administer 20µl of Blo t extracts to the nares of mice nostril and after all the 
mice have been inoculated, turn off isofluorane flow and oxygen tap. Transfer 
the mice back into the cage until they are fully recovered from isofluorane 
anesthesia. 
5. Remove the anesthetized mouse from the chamber and administer 20µl of 
OVA solution to the nares of the nostril. Place the mouse back in the chamber 
to keep it under anesthesia. Repeat with all the mice until they have received 
the inoculations. Put them back into the cage. 
6. After all the mice have been inoculated, turn off the isofluorane and oxygen 
taps. 
7. After 3 successive days of intranasal challenges the mice are ready for 
experimentation on day 24. 
2.4.4 Sensitization and challenge protocol (intransal sensitization) 
 




1. Day 0: sensitize mice through intransal route (i.n) with 100µg Blo t extracts. 
Knockdown mice through isofluorane anesthesia as described earlier. 
2. Day 7-9: consecutively challenge mice with 10µg Blo t extracts via intranasal 
route.  
3. Day11: mice were examined with or without after being sacrificed via carbon 
dioxide asphyxiation.  
Important notes:  
• In some experiments, mice were sacrificed and examined at early time points 
(24hr, 48hr, 72hr et al) after initial administration of Blo t (100µg).  
• In some experiments, Blo t was admixed with 100 μg Endotoxin-free OVA 
(Profos, Germany) or 50 μg AlexaFluor 647 OVA conjugate (Invitrogen, 
Singapore) or pertussis toxin (Sigma, Singapore). 
• In the case of Langerin-eGFP-DTR mice, mice were injected via 
intraperitoneal route with 8ng/g body weight of diphtheria toxin (DT) 
(Sigma-Aldrich) to deplete CD103+ (co-express with Langerin) DCs.  
• In some experiments, GM-CSF was neutralized with 50 μg polyclonal goat 
anti-mouse GM-CSF (R&D Systems, USA) via intranasal route. In GM-CSF 
supplementation experiments, mice were treated i.n. with 1 μg recombination 
mouse GM-CSF (Peprotech, USA).  
2.5 Bronchoalveolar lavage (BAL) analysis 




1. Cannulate the trachea of sacrificed mice with a needle with plastic tubing and 
flush the lungs with 1ml MACS buffer three times. Transfer the instillation 
into eppendorf tube.  
2. Spin down the cells at 450g for 5 minutes and harvest the supernatant (BALF) 
for cytokine measurement by ELISA.  
3. Perform RBC lysis by suspending the cells in 0.2ml of RBC lysis buffer if 
apparent red blood cells were observed in the cell pellet. This was done at 
room temperature for 1 minute or so. Red blood cell lysis was quenching by 
adding 1ml MACS buffer. 
4. Spin down the cells and wash the cells with another 1ml MACS buffer. 
5. Re-suspend the cells in 0.5ml MACS after pelleting and obtain cell number in 
BAL fluid by using haemocytometer.  
6. Perform flow cytometry antibody staining after pelleting: Siglec-F-PE (BD 
biosciences, USA), Ly-6G-APC (BD biosciences, USA), CD11c-PerCP/Cy5.5 
(Biolegend, USA) and CD3-PB (Biolegend, USA) and analyze further through 
flow cytometry machine (Beckman Coulter, USA) to gain differentiate cell 
counts.  
 
2.6 Ex vivo assays of mediastinal lymph node (MLN) 
2.6.1 Ex vivo restimulation of MLN cells 
 




MLN was harvested from sacrificed mice and physically disrupted by pushing through 
a 70µm cell strainer to obtain a single cell suspension. Cells were subsequently cultured 
in U-bottom 96 microplates at a cell density of 2,000,000/ml in complete RPMI with 
the stimulation of 20 μg/ml Blo t extracts. Supernatants were harvested after 5 day 
culture and further analyzed. 
2.6.2 Intracellular cytokine staining of re-stimulated MLN cells 
 
1. For intracellular staining of cytokines in cells, synthesis of cytokines was 
stimulated by additional stimulus. Cells were further stimulated with PMA and 
Ionomycin (Sigma Alrich) and cytokine secretion from the cells was blocked 
by Golgiplug containing brefeldin A (BD Pharmingen) and Golgistop 
containing monensin (BD Pharmingen) for 6 hr.  
2. Cells were initially stained with CD4-PE-Cy7 (RM4-5; Biolegend) for 30 
minutes at 4°C. 
3. After washing with FACS buffer, cells were pelleted and further washed in 
PBS buffer. Re-suspend the cells at a density of 1 million per ml in PBS buffer. 
1µl fixable live/dead dye (Invitrogen, Singapore) was added into the cell 
suspension and cells were incubated for 30 minutes at 4°C. 
4. After incubation, wash the cells with PBS buffer twice.  
5. Fix and permeabilize the cells with fixation/ permeabilization buffer for 30 
minutes at 4°C. 
6. Wash cells with permeabilization/wash buffer twice. 




7. Stain the cells with conjugated intracellular antibodies IL-4-APC (11B11; BD 
Pharmingen) and IFN-γ-PE (XMG1.2; BD Pharmingen).  
8. Wash cells with permeabilization/wash buffer twice and re-suspend in FACS 
buffer for flow cytometry analysis.  
2.6.3 Ex vivo analysis of IL-4-producing innate and adaptive cells in MLN 
1. MLN was harvested from sacrificed 4get mice and physically disrupted by 
pushing through cell strainer as described earlier to obtain single cell 
suspension. 
2. Cells were stained with CD3-Percp/Cy5.5 (145-2C11, eBioscience), CD19- 
PerCP/Cy5.5 (1D3, eBioscience), CD4-eFluor450 (GK1.5, eBioscience), 
CD49b-PE-Cy7 (DX5, eBioscience), FcεR1-PE (MAR-1, eBioscience) and 
CD117-APC (2B8, eBioscience) for flow cytometry analysis. IL-4-eGFP was 
simultaneously measured under FITC (FL-1) channel.  
Important note: In the case of MLN from CD4 T cell adoptive transfer recipients, 
cells were stained with anti-mouse DO11.10 clonotypic TCR-PE (KJ1-26; BD 
Pharmingen), CD3-APC (145-2C11; eBioscience) and CD4-PE-Cy7 (RM4-5; 
Biolegend). IL-4-eGFP was simultaneously measured under FITC (FL-1) channel.  
2.6.4 Ex vivo antigen presentation assay of MLN dendritic cells 
1. Sorted CD4 T cells were labeled with violet CFSE as described earlier and 
plated at a density of 100,000 cells/well in the presence of sorted DCs (5 T 
cells: 1 DC ratio).  




2. After 4 day culture, cells were harvested and OVA-specific T cell proliferation 
was determined by staining cells with anti-mouse DO11.10 clonotypic 
TCR-PE, CD3-APC and CD4-PE-Cy7. 7-Amino-actinomycin D (Sigma, 
Singapore) was added 5 min before sorting to differentiate live/dead cells, 
according to the manufacturer’s instruction.  
2.6.5 Ex vivo analysis of MLN dendritic cells 
1. MLN was collected from sacrificed mice and digested with Liberase as 
described earlier for 30 minutes.  
2. Digested MLN was physically disrupted by pushing through a 70µm cell 
strainer to obtain a single cell suspension. 
3. Cells were stained with different panels of antibodies for further flow 
cytometry analysis:  
• To examine migratory DC compartments in MLN, cells were stained 
with I-A/I-E-eFluor450 (M5/1114.15.2; eBioscience), CD11c-FITC 
(N48; eBioscience), CD24-PE-Cy7 (M1/69; Biolegend), CD64-PE 
(X5-5/7.1; Biolegend), CD103- APC (2E7; eBioscience) and 
CD11b-PerCPCy5.5 (M1/70; eBioscience), CD40-APC (1C10; 
eBioscience) or CD80-APC (16-10A1; eBioscience) or CD86-APC 
(GL1; eBioscience) 
• To determine OVA-AF647 uptake of migratory DCs in MLN, cells 
were stained with CD103-biotinylated anti-CD103 (2E7; eBioscience) , 
followed by eFluor 605NC conjugated streptavidin (eBioscience), 




I-A/I-E-V500 (M5/1114.15.2; BD horizon), CD11c-PerCPCy5.5 
(N418; Biolegend), CD24-eFluor450 (M1/69; eBioscience); CD64-PE 
(X5-5/7.1; Biolegend), and CD11b-APC-eFluor 780 (M1/70; 
eBioscience). OVA-AF647 was simultaneously measured via APC 
channel.  
 
2.7 Ex vivo assays for lung parenchymal  
2.7.1 Cytokine assay for lung homogenate 
 
1. Lung was harvested and homogenized with tissue homogenizer in 250 μl 
Radio-Immunoprecipitation Assay (RIPA) Buffer (Sigma, Singapore). 
2. Lung homogenate was spun down to pellet debris. Cleared lysate was 
collected and protein concentration was quantitated using Bradford Assay 
(Bio-Rad, Singapore) according to the manufacturer’s protocol.  
3. Cytokines were measured by ELISA on lung homogenates and data obtained 
was normalized by total protocol content.  
2.7.2 Cytokine assay for sorted lung cells 
1. As described earlier, harvested lungs were finely cut with scissors, digested 
with Liberase for 30 minutes and physically pushed through cell strainer to 
obtain single cell suspension. Digested lung cells were thoroughly washed 
with MACS buffer, followed by RBC lysis to remove as many RBC as 
possible.  




2. Subsequently, cells were stained with CD45-APC (30-F11, eBioscience) and 
7-Amino-actinomycin D was added 5 min before sorting to differentiate 
live/dead cells. 
3. Cells were sent for sorting and collected in neat FCS. 
4. Sorted cells were cultured at a density of 2.5 million cells/ml in 96-well 
microplate. Supernatant was harvested 18 hr later and ELISA was performed 
to measure cytokine production within the supernatant.  
2.7.3 GM-CSF receptor expression measurement of lung dendritic cells 
 
1. Lung was excised, cut into small pieces, and digested in Liberase as described 
earlier for 30 minutes before physical disruption into single-cell suspension by 
passing through cell strainer.  
2. DCs were enriched by density centrifugation using Optiprep. Where necessary, 
DCs were further enriched by positive selection with CD11c MACS beads as 
described earlier.  
3. Cells were stained with CD103-biotinylated anti-CD103 (2E7; eBioscience) , 
followed by eFluor 605NC conjugated streptavidin (eBioscience), 
I-A/I-E-V500 (M5/1114.15.2; BD horizon), CD11c-PerCPCy5.5 (N418; 
Biolegend), CD24-eFluor450 (M1/69; eBioscience); CD64-PE (X5-5/7.1; 
Biolegend), CD11b-APC-eFluor 780 (M1/70; eBioscience) and 
GM-CSF-receptor alpha chain-APC (698423; R&D system). 
4. Cells were examined by flow cytometry analysis.  
 




2.8 Lung histology 
2.8.1 Preparation of lung tissue 
 
1. Place the sacrificed mouse on its back on a paraffin block. 
2. Spread the forelimbs and secure each paw to the rack with a surgical towel 
clamp or a pin if on a paraffin block.  
3. Make a cut along the abdomen to expose the internal organs until the left 
kidney is seen. 
4. Make a cut at the renal artery to deplete circulating blood. 
5. Cut the diaphragm laterally on both sides and cut toward the head across ribs 
and parallel to lungs. The heart is now exposed. 
6. Cut the left atrium to allow blood and perfusion fluid to be released when 
perfusion starts. 
7. With left hand, use a small pair of forceps to grasp ventral tip of the heart. 
8. With right hand, make a small cut at the right ventricle, size enough for the 
cannula tip. 
9. With right hand, insert the cannula and direct it up through the right ventricle 
until the tip of the cannula is visible within the aorta. 
10. Perfuse the lung using a 50ml syringe. Push slowly through the cannula until 
the lung turns pale white.  




11. After perfusion, cannulate the trachea with a needle with plastic tubing and 
push in 0.7ml of 4% Paraformaldehyde or 1% formalin to fix the lung.  
12. Put the perfused and fixed lung tissues in 4% Paraformaldehyde or 1% 
formalin for 2-5 days before processing. 
2.8.2 Processing and sectioning of lung tissue 
 
Treat tissues as stated below using the Leica tissue processor: 
1. 75% ethanol 1 hour  
2. 80% ethanol 1 hour 
3. 90% ethanol 1 hour 
4. 100% ethanol 1½ hours 
5. 100% ethanol 1½ hours 
6. 100% ethanol 1½ hours 
7. Histoclear 2 hours 
8. Histoclear 2 hours  
9. Histoclear   2 hours 
10. Paraffin    2.5 hours 
11. Paraffin   2.5 hours 
2.8.3 Tissue mounting  
1. Transfer tissue from wax to embedding mold. 




2. Place cassette to hold tissue on top of mold. 
3. Top up with enough wax to hold tissue to the cassette. 
4. Transfer mold with hot wax and cassette to a cold surface (e.g. ice) and wait 
for wax to solidify. 
5. Remove embedded tissue from mold using a forceps. 





• Slides with paraffin sections 
• Histoclear (Sigma Aldrich, USA) 
• Ethanol (100%, 95% and 70% in distilled water) (Merck, USA) 
• Differentiation solution: acidic ethanol. (0.3% HCl in 70% ethanol) 
• Haematoxylin (Harri’s) (Sigma-Aldrich, USA) 
• Scott’s tap water: 3.5g Sodium carbonate (Na2CO3) and 20g magnesium sulfate 
(MgSO4 * 7H2O) in 1L distilled water 
• Alcoholic Eosin Y (Sigma-Aldrich, USA) 
• Histomount (Invitrogen, USA) 
2.7.4.2 Procedures 
Deparaffinize and rehydrate sections as follows: 
1. Histoclear   10 mins 
2. Histoclear   10 mins 




3. 100% ethanol 2 mins 
4. 100% ethanol 2 mins 
5. 95% ethanol 10 dips 
6. 70% ethanol 10 dips 
7. Rinse in distilled Water 
For Haematoxylin and eosin staining: (after deparaffinization and rehydration) 
1. Stain in Haematoxylin for 5 mins. 
2. Rinse in distilled Water. 
3. Differentiate in 0.3% acidic ethanol for 30 seconds to 1 minute. 
4. Rinse in distilled water. 
5. Blue in Scott’s tap water for 1 min. 
6. Rinse in distilled Water. 
7. Check under microscope for blue nuclear chromatin. Blue again in Scott’s 
tap water if bluing is insufficient and check under microscope again. 
8. Dehydrate in 70% ethanol for 2 mins. 
9. Stain in alcoholic eosin for 30 seconds. 
10. Rinse in 70% ethanol.  
11. Dehydrate and clearing: 
a. 95% Ethanol 10 dips 
b. 100% Ethanol 10 dips 
c. Histoclear  10 mins 
12. Mount the slides with mounting medium. 





Nuclear chromatin: Blue 
Nucleoli:   Visible 
Cytoplasm:   Pink  
For Periodic acid staining (after deparaffinization and rehydration) 
1. Oxidize in periodic acid solution for 5 mins.  
2. Rinse in distilled Water. 
3. Place in Schiff’s reagent for 15 mins.  
4. Rinse the slides under running tap water for 5 mins. 
5. Counterstain in Haematoxylin for 1.5 mins. 
6. Wash in tap water.  
7. Dehydrate and clearing: 
a. 70% ethanol 10 dips  
b. 95% ethanol 10 dips 
c. 100% ethanol 10 dips 
d. Histoclear 10 mins 
8. Mount the slides in mounting medium. 
Result: 
Nuclear chromatin: Blue 
Nucleoli :  Visible 
Mucus:  Pink purple  
 




2.9 Lung immunofluorescence histology  
1. As described earlier, sacrificed mouse was mounted against paraffin plate and 
lung was perfused with PBS buffer. 
2. Lung was fixed with 2% paraformaldehyde with 30% sucrose overnight and 
washed in PBS buffer for 1 h on a rotator, followed by embedding in optimum 
cutting temperature compound (Sakura FineTek).  
3. Sections 5µm in thickness were cut on a cryostat (Leica) and were kept at 
-20oC. Cryosections were air-dried and blocked with PBS with 0.2% BSA. 
4. Sections were then stained with rabbit anti-mouse GM-CSF (1:200 dilution; 
FL-144; Santa Cruz) and rat anti-mouse EpCAM (1:800 dilution; G8.8; 
eBioscience) in PBS containing 1% normal mouse serum overnight at 4°C.  
5. Cy3-conjugated anti-rabbit antibody (1:300 dilution; 711-166-152; Jackson 
ImmunoResearch) and AF647-conjugated anti-rat antibody (1:400; A21247; 
Invitrogen) were used for detection.  
6. Sections were counterstained with 4, 6-diamidino-2-phenylindole (KPL) for 
visualization of cell nuclei and mounted with fluorescent mounting medium 
(Dako, USA) for analysis.  
7. Images were taken with a fluorescence microscope (Axio imager.Z1, Axiocam 
HRM camera; 10x/0.3, magnification ×100 and ×40/0.75, magnification 400x 
EC Plan-NEOFLUAR objective lenses; Carl Zeiss Micro Imaging, Inc., Jena, 
Germany). 
2.10  Assessment of lung function 




1. Prepare Methacholine (Sigma Aldrich, USA) solution at different 
concentrations. (Concentrations at 0.5, 1, 2, 4, 8mg/ml). 
2. Connect the whole system, the FinePointe™ series RC system (Buxco 
Research System, USA). 
3. Initiate the FinePointe™ Review software. 
4. Calibrate the System. 
5. Anesthetize the mouse with an anesthesia cocktail with ketamine (100mg/kg) 
and Medetomidine (15mg/kg) obtained from the pharmacy of the animal 
holding unit by i.p. injection. Wait for around 5-10 minutes until there is no 
reflex. 
6. Perform Tracheotomy, insert the cannula and tie it. 
7. Put the mouse into the chamber and connect the cannula with the metal tube of 
the chamber. 
8. Ventilate the mouse with stroke volume at 200μl/breath and breath frequency 
at 150/min. 
9. Wait for 1-3mins to make sure the breathing of the mouse is synchronized to 
the ventilator. 
10. Click “Recording” and input study name & ID of the mouse and then Press 
“Run”. Record airway resistance (RI) and dynamic compliance (Cdyn). 
11. Inject 10μl PBS with pipette via the aerosol nebulizer.  




12. Immediately press button “OK” (on the FinePointe™ RC system or the 
FinePointe™ software) to start signal recording as soon as the injection is 
finished. 
13. Inject different concentrations of Methacholine solution when the machine 
instruction to load next dosage is initiated.  
14. Take the mouse out from the chamber and sacrifice it by carbon dioxide 
euthanasia. 
15. Dispose the mouse carcasses properly through comparative medicine center. 
16. Save the data and perform analysis on Finepointe™ when the Methacholine 
challenge is over. 
 
2.11 Measurement of cytokines  
IL-4, IL-5, IL-10, IL-12, IL-13, IFN-γ, TSLP, IL-25, IL-33 and GM-CSF levels are 
detected using commercially available DuoSet ELISA kits (R&D systems, USA). 
Capture antibodies, detection antibodies and standards for individual cytokine were 
reconstituted according to manufacturer’s instruction.  
Plate preparation 
1. Dilute the capture antibody to the working concentration in PBS without 
carrier protein. Immediately coat a 96-well microplate with 100µL per well of 
the diluted capture antibody. Seal the plate and incubate overnight at room 
temperature. 




2. Aspirate each well and wash with wash buffer, repeating the process two times 
for a total of three washes. Wash by filling each well with wash buffer using a 
squirt bottle, manifold dispenser or autowasher. Complete removal of liquid at 
each step is essential for good performance. After the last wash, remove any 
remaining wash buffer by aspirating or by inverting the plate and blotting it 
against clean paper towels. 
3. Block plates by adding 300µL of assay diluent to each well. Incubate at room 
temperature for a minimum of 1 h. 
4. Repeat the aspiration wash as in step 2. The plates are now ready for sample 
addition. 
Assay procedure 
1. Add 100µL of sample or standard in assay diluent or an appropriate diluents 
per well. Cover with an adhesive strip and incubate 2 hours at room 
temperature. 
2. Repeat the aspiration/wash as in step 2 of plate preparation. 
3. Add 100µL of the detection antibody, diluted in assay diluent, to each well. 
Cover with a new adhesive strip and incubate for 2 hours at room temperature. 
4. Repeat aspiration/wash as in step 2 of plate preparation. 
5. Add 100µL of the working dilution of Streptavidin-HRP to each well. Cover 
the plate and incubate for 20 minutes at room temperature. Avoid placing the 
plate in direct light. 
6. Repeat the aspiration/wash as in step 2. 




7. Add 100µL of the substrate solution to each well. Incubate for 20 minutes at 
room temperature. Avoid placing the plate in direct light. 
8. Add 50µL of stop solution to each well. Gently tap the plate to ensure 
thorough mixing. 
9. Determine the optical density of each well immediately using a microplate 
reading set to 450nm. If wavelength correction is available, set to 540nm or 
570nm, if wavelength correction is not available; subtract readings at 540nm 
or 570nm from the readings at 450nm. This subtraction will correct for optical 
imperfections in the plate. Readings made directly at 450nm without 
correction may be higher and less accurate. 
2.12 Measurement of serum immunoglobulins  
The same buffer as cytokine ELISA is used in serum immunoglobulin assay except 
for the coating buffer. 0.1M sodium carbonate (pH=9.5) is used instead of PBS as 
coating buffer. (7.13 g NaHCO3 and 1.59 g Na2CO3 in 1.0 L distilled water; pH 
adjusted to 9.5 with 10N NaOH) 
2.12.1 ELISA for total IgE  
Mouse total IgE was measured by Mouse IgE ELISA Set (BD Bioscience, USA). 
Capture antibodies, detection antibodies and standards for individual cytokine were 
reconstituted according to manufacturer’s instruction. 
Plate preparation 
1. Coat microplate with 100 µL per well of capture antibody diluted in Coating 
Buffer. Seal plate and incubate overnight at 4°C. 




2. Aspirate wells and wash 3 times with 200 µL/well wash buffer. After last 
wash, invert plate and blot on absorbent paper to remove any residual buffer. 
3. Block plates with 200 µL/well assay diluent. Incubate at room temperature 
(RT) for 1 hour. 
4. Aspirate/wash as in step 2. 
Assay procedure 
1. Prepare standard and sample dilutions in assay diluent. Pipette 100 μL of 
each standard, sample, and control into appropriate wells. Seal plate and 
incubate for 2 hours at RT. 
2. Aspirate/ wash as in step 2, but with 5 total washes. 
3. Add 100 μL of prepared working detector (detection antibody + 
Streptavidin-HRP reagent) to each well. Seal plate and incubate for 1 hour 
at RT. 
4. Aspirate/ wash as in step 2, but with 7 total washes. NOTE: In this final 
wash step, soak wells in wash buffer for 30 seconds to 1 minute for each 
wash. 
5. Add 100 µL of substrate solution to each well. Incubate plate (without 
plate sealer) for 30 minutes RT in the dark. 
6. Add 50 µL of stop solution to each well. 
7. Read absorbance at 450 nm within 30 minutes of stopping reaction. If 
wavelength correction is available, subtract absorbance 570 nm from 
absorbance 450 nm. 




2.12.2 ELISA for Blo t-specific IgE 
Plate preparation 
1. Coat 96-well microplate with 100µl Blo t (20µg/ml) extracts per well. Seal the 
plate and incubate overnight at 4°C. 
2. Aspirate each well and wash with Wash Buffer as described before. 
3. Block plates by adding 300µL of Reagent Diluent to each well. Incubate at 
room temperature for a minimum of 1 h. 
4. Repeat the aspiration wash as in step 2. The plates are now ready for sample 
addition. 
Assay procedure 
1. Add 100µL of mouse serum with appropriate diluent ion per well. Cover 
with an adhesive strip and incubate 2 hours at room temperature. 
2. Repeat the aspiration/wash as in step 2 of plate preparation. 
3. Add 100µL of anti-mouse IgE biotin conjugate (BD Pharmingen, USA) 
for 2 hours.  
4. Wells were washed three times and incubated with streptavidin conjugated 
Alkaline Phosphatase (BD Pharmingen, USA) for 30 minutes. 
5. Wells were washed 6 times and substrate p-Nitrophenyl phosphate (Sigma, 
USA) was added into each well. 
6. Incubate for 20 minutes at room temperature. Avoid placing the plate in 
direct light. 
7. Determine the optical density of each well immediately using a microplate 
reading set to 450nm as described before.  




2.12.3 Dotblots for Blo t-specific IgE and IgG 
1. The total protein (Blo t extracts) loaded for each allergen source was 1ug. All 
allergen sources were dotted in duplicate for each set of the array. The dotted 
membranes were then left to dry overnight.  
2. After drying, membranes were blocked with wash buffer (same as ELISA) for 
1 hour and subsequently washed three times.  
3. Then the membranes were incubated with respective moue sera overnight at 
4°C. 
4. For IgE, membranes were washed followed by incubation with anti-mouse IgE 
biotinylated for 2 hours.  
For IgG, membranes were washed and incubated with streptavidin-alkaline 
phosphatase for 30 minutes. Membranes were washed and further incubated 
with anti-mouse IgG (Sigma, Singapore) alkaline phosphatase conjugated 
antibodies for another 2 hours.  
5. Washing was performed after incubation. The positive binding to allergen was 
visualized by developing the membrane with 
5-bromo-4-chloro-3-indolyl-phosphate/nitro-blue tetrazolium color substrate 
(BD Pharmingen, USA).  
6. Developed membranes were dried and scanned. The reaction intensities were 
measured using Olympus MicroImage software. 
2.13 Gel Filtration of Blo t extracts 




1. Blo t extracts were applied to equilibrated Superdex 75 10/300 GL column 
(GE Healthcare, USA) according to manufacturer’s instruction. 
2. Sample was eluted with 50µM phosphate buffer (0.5M phosphate +0.15M 
NaCl, pH=7.0).  
3. Fractions of 0.5ml were collected for the length of elusion and pooled into 
fifteen bigger fractions based on final elution profile. 
4. Pooled fractions were concentrated and tested experimentally.  
5. Active fractions were subsequently analyzed by reduced SDS-PAGE. 
 
2.14 In vivo and in vitro assays for bone marrow-derived dendritic cells 
2.14.1 Generation of GM-CSF-derived bone marrow dendritic cell (BMDCs) 
1. Tibia and femur of mice were excised with surrounding tissue removed and 
exposing the bones.  
2. The ends of tibia and femur were cut and bone marrow was flushed from each 
of the shafts using RPMI1 (RPMI with 1% FCS).  
3. Single cell suspension was obtained by passing bone marrow through cell 
strainer.  
4. Cells were pelleted by centrifugation at 300g for 7 minutes.  
5. Red blood cell lysis was carried out using red blood cell lysis buffer (150mM 
NH4Cl, 10mM KHCO3 and 0.1mM EDTA) for 1 min.  
6. Cells were centrifuged at 300g for 7 mins and washes were repeated with 
RPMI1 for another 2 times.  




7. Bone marrow cells were cultured at a concentration of 1 x 106 cells/ml in 
complete RPMI with 10% FCS with 20ng/mL of mouse recombinant 
GM-CSF (Peprotech , USA) in a 12 well plate with 2ml per well.  
8. At Day 2 and Day 4, 75% of the media was removed and replenished with 
fresh media containing 20ng/mL of GM-CSF.  
9. At day 6, the plate was gently tapped to dislodge DC aggregates. Media was 
aspirated completely and the wells were washed once along the walls with 
warm RPMI1.  
10. Centrifugation was carried out at 300g for 7 minutes.  
11. Cell pellet was washed twice with RPMI1 by centrifugation at 300g for 7 
minutes.  
12. After the final wash, cell pellet was re-suspended with complete RPMI and 
ready for usage. Approximately 70-75% of the BMDCs will be CD11c+. 
2.14.2 Immunization of mice with BMDCs  
1. BMDCs were seeded at a density of 1 million cells/ml in 6-well tissue culture 
plate pulsed by Blo t extracts.  
2. After overnight culture, aspirate non-adhesion cells and harvest cells attached 
to the bottom of well. 
3. Wash thoroughly with PBS buffer three times by centrifugation. 
4. Re-suspend BMDCs in PBS buffer at a concentration of 10 million cells per 
ml.  




5. Transfer 1 million BMDCs (in 100µl solution) into naïve mouse which has 
been knocked out by isofluorane via intratracheal route. 
6. 10 days later, mice were challenged with Blo t for three consecutive days via 
intranasal and sacrificed one day after final challenge for further examination 
and analysis. 
2.14.3 Stimulation of BMDCs with lipopolysaccharides (LPS)  
1. BMDCs were seeded at a density of 1 million cells/ml in 96-well microplate 
pulsed by 100µg/ml Blo t extracts with the presence of LPS at different 
concentration.  
2. After overnight culture, supernatant was saved for ELISA detection and cells 
were collected and stained with following conjugated antibodies for flow 
cytometry analysis: I-A/I-E-eFluor450, CD11c-FITC, CD40-APC or 
CD80-APC or CD86-APC. 
2.14.4  Co-culture of BMDCs and CD4 T cells  
1. BMDCs were co-cultured with CD4 T cells at in 96 well round bottom plates 
and incubated at 37°C and 5% CO2 for 5 days (1 BMDC: 5 T cells).  
2. Cells were further re-stimulated by PMA/ionomycin with the presence of 
Golgiplug and GolgiStop for 6 hrs as described earlier. 
3. Surface marker staining was performed (CD4-PE-Cy7), followed by fixable 
live/dead staining and fixation/permealization as described earlier.  
4. Subsequently, intracellular cytokine staining was performed (IFN-γ-PE) and 
cells were analyzed by flow cytometry.  




2.15  Statistical analysis 
Unpaired Student’s t test is used for comparison between two groups and one-way 
ANOVA is used for comparison within multiple groups. Data is expressed as mean ± 
SEM (*p < 0.05, **p < 0.01 and ***p < 0.001 were indicated). For Flow cytometry 








CHAPTER 3: Murine Model of Asthma Induced by Blo t allergen 
 
3.1 Introduction  
In this chapter, firstly we adopted the commonly used prime-boost protocol with alum 
as adjuvant via systemic sensitization route (intraperitoneal) to validate the strong 
allergenicity of Blo t. Of greater relevance, we established a new murine model of 
asthma using crude extracts of Blo t via intranasal administration, in the absence of 
any exogenous adjuvant. Human asthma has at least three identifiable clinical 
presentations: acute inflammation, chronic inflammation and airway remodelling 
(Bousquet et al., 2000) and numerous chronic asthma models have been developed to 
either examine the pathological features of asthma or test the therapeutic efficacy of 
different agents (Kumar and Foster, 2001; Wegmann, 2008). In our study we 
employed an acute immunization protocol and primarily focus on investigating the 
cellular and molecular mechanisms of Th2 responses initiation during priming stage 
of allergen sensitization.  
3.2 Blo t induces a profound airway allergy phenotype through systemic 
sensitization.  
3.2.1 Immunization protocol (systemic sensitization) 
Firstly, we immunized the mice via intraperitoneal route with alum as adjuvant which 
is commonly used in classic OVA model to confirm the robustness of Blo t as dust 




mite allergen. Mice were intraperitoneally (i.p) sensitized with Blo t (day 0) or with 
vehicle (PBS) as control and boosted (i.p) on day 14, followed by intranasal (i.n) 




Figure 3.2.1 Immunization protocol (systemic sensitization).  
C57BL/6 mice were sensitized and boosted on day 0 and day 14 via intraperitoneal 
route with either Blo t-alum or PBS-alum respectively. Consecutive intranasal 
challenges with either Blo t or PBS were conducted from day 21 to day 23 and mice 
were sacrificed on day 24 to be examined.  
3.2.2 Increased serum immunoglobulin E production  
Serum immunoglobulin E (IgE) was measured using ELISA to evaluate the humoral 
immune response of Blo t immunization. As can be seen in Figure 3.2.2, IgE level 
was elevated in Blo t immunized and challenged mice, compared to PBS treated 
control group.  





Figure 3.2.2 Immunoglobulin E (IgE) in the serum of immunized mice.  
Mice were immunized with Blo t-alum (PBS-alum for control mice)(i.p) on day 0 and 
day 14 and further challenged with Blo t (PBS as control) (i.n) from day 21 to day 23. 
On day 24, mice were sacrificed and peripheral blood was collected for IgE 
measurement using ELISA. Data is expressed as mean ± SEM (*p < 0.05, **p < 0.01 
and ***p < 0.001 were indicated). n=12 
3.2.3 Increased eosinophil and lymphocyte infiltration in the airway  
Massive inflammatory cell infiltration in the airway has been identified as one of the 
most important hallmarks of asthma both in patients and animal models (Rosenberg et 
al., 2007). For years, cell counting under microscope has been employed to obtain 
differential cell counts (eosinophils, neutrophils, macrophages and lymphocytes) 
based on their distinctive morphological properties. However, it is easy to confuse 
immature neutrophils with eosinophils so in this study, we utilized flow cytometry 
antibody staining to differentiate cells in the BAL fluid (Figure 3.2.3 and 3.2.4). 
Following the protocol described earlier, we observed significantly increased 
eosinophil and lymphocyte infiltration in the BAL fluid of mice immunized and 
challenged with Blo t, compared with control mice (Figure 3.2.1.5). More neutrophils 




were also found in the BAL of Blo t-treated mice and this could be either due to the 
presence of endotoxin within the extracts (through at a low level) or the bystander 
effect of inflammatory environment. Nevertheless, dominant eosinophilia suggests a 
robust Th2 allergic asthma-like response was induced by Blo t via systemic 
sensitization and respiratory challenge route. 
 
 
Figure 3.2.3 Infiltration of cells into the airways in response to asthmatic.  
Mice were immunized on days 0 and 14 with OVA-alum (PBS-alum as control) and 
challenged with OVA (PBS-alum as control) on days 21-23. Mice were sacrificed on 
day 24 for the collection of samples. Cells from the BAL fluid were stained with 
CD11c, Siglec-F and Ly-6G for flow cytometry analysis. Eosinophils: Siglec-F+ 
CD11c-; Neutrophil: CD11c-Ly-6G+; Macrophages: CD11c+ Siglec-F+ Ly-6G-. 
(Courtesy of Dr Yafang Tang) 
 





Figure 3.2.4 Images of sorted BAL fluid cells (H&E staining).  
Mice were immunized on days 0 and 14 with OVA-alum and challenged with OVA 
on days 21-23. Mice were sacrificed on day 24 for the collection of samples. Cells 
from the BAL fluid were stained with CD11c, Siglec-F and Ly-6G for cell sorting. 
(A). Representative image of Siglec-F+CD11c+Ly-6G- macrophages (granular 
nucleus and extensive cytoplasm). (B). Representative image of Siglec-F+CD11c- 
eosinophils (donut-shaped multi-nuclei and pink cytoplasm). (C) Representative 
image of CD11c-Ly-6G+ neutrophils (irregular-shaped multi-nuclei and transparent 
cytoplasm). (Courtesy of Dr Yafang Tang) 
 
Figure 3.2.5 Cell infiltration in BAL fluid of Blo t-treated mice.  
Mice were immunized with Blo t-alum (PBS-alum for control mice)(i.p) on day 0 and 
day 14 and further challenged with Blo t (PBS as control) (i.n) from day 21 to day 23. 
Mice were sacrificed on day 24 and samples were collected for further examination. 
Cells from BAL fluid were harvested and stained with CD11c, Siglec-F, Ly-6G and 




CD3 for flow cytometry analysis to obtain differential cell counts of eosinophils 
(CD11c- Siglec-F+), macrophages (CD11c+ Siglec-F+ Ly-6G-), lymphocytes (CD11c- 
Siglec-F- Ly-6G- CD3+) and neutrophils (CD11c- Ly-6G+). Data is expressed as mean 
± SEM (*p < 0.05, **p < 0.01 and ***p < 0.001 were indicated). n=9 
 
3.2.4 Elevated Th2 cytokine production in mediastinal lymph node  
The Mediastinal lymph node (MLN) has been shown to be the main lung draining 
lymph node and the dominant source of T cells in allergic response (Hammad et al., 
2010). Thus, examination of MLN can provide direct evidence of T cell polarization 
status in our asthma model. We harvested MLN from mice that have been immunized 
and challenged as described earlier, re-stimulated cells from MLN with Blo t and 
collected the supernatant for ELISA. Enhanced signature Th2 cytokines, IL-4 and 
IL-5, were detected in Blo t-treated mice, whereas Th1 cytokine IFN-γ remained 
undetectable (Figure 3.2.6).  
  
Figure 3.2.6 Cytokine production from lung draining lymph node (MLN) of Blo 
t-treated mice.  
Mice were immunized with Blo t-alum (PBS-alum for control mice) (i.p) on day 0 
and day 14 and further challenged with Blo t (PBS as control) (i.n) from day 21 to day 




23. Mice were sacrificed on day 24 and samples were collected for further 
examination. MLN was harvested, processed and re-stimulated with Blo t for 5 days. 
Cytokines in the supernatant was measured by ELISA. Data is expressed as mean ± 
SEM (*p < 0.05, **p < 0.01 and ***p < 0.001 were indicated). n=9 
3.3 Blo t induces a robust airway allergy phenotype through respiratory 
sensitization.  
3.3.1 Immunization protocol (respiratory sensitization) 
To resemble route of allergen sensitization with clinical relevance, we established an 
immunization and challenged protocol solely via respiratory administration (intranasal) 
without the presence of any exogenous adjuvant. Mice were intranasally sensitized 
with Blo t on day 0, followed by successive daily challenge from day 9 to day 11 
(Figure 3.2.2.1). On day 14, mice were sacrificed and samples were collected for 





Figure 3.3.1 Immunization protocol (respiratory sensitization).  
C57BL/6 mice were sensitized on day 0 via intranasal route with either Blo t or PBS 
respectively. Consecutive intranasal challenges with either Blo t or PBS were 
conducted from day 9 to 11 and mice were sacrificed on day 14 to be examined. 




3.3.2 Increased serum immunoglobulin E production  
Total serum immunoglobulin E (IgE) and Blo t-specific IgE were measured using 
ELISA and dot-blot to determine the Blo t-specific IgE level. As shown in Figure 
3.3.2, repeated respiratory exposure of Blo t induced elevated total IgE and Blo 
t-specific IgE production in Blo t-treated mice. On the other hand, we did not see 
significant increase in the level of Blo t-specific IgG from the serum of mice with 
solely intranasal administration (i.n mice), whereas elevated IgG level was detected 
with systemic sensitization (i.p mice). This data strengthens our claim that murine 
model induced by inhaled Blo t independence of any exogenous adjuvant serves as a 
closer mimicry of human asthma, wherein serum IgE, instead of IgG, was the one of 



















Figure 3.3.2 Immunoglobulins in the serum of Blo t immunized mice.  
(A) Mice were sensitized on day 0 via intranasal route with either Blo t or PBS 
respectively. Consecutive intranasal challenges with either Blo t or PBS were 
conducted from day 9 to 11 and mice were sacrificed on day 14 to be examined. 
Peripheral blood was collected to obtain serum for total IgE ELISA assay. Data is 
expressed as mean ± SEM (*p < 0.05, **p < 0.01 and ***p < 0.001 were 
indicated).n=12 (B) Peripheral blood was collected from both i.p mice and i.n mice 
(as described earlier) for ELISA and dot-blot assay. (Serum from 15 samples per 
treatment group were pooled and tested for Fig 3.2.2B data points).  
3.3.3 Increased eosinophils and lymphocytes in the airway  
As shown in Figure 3.3.3, repeated respiratory exposure to Blo t without exogenous 
adjuvant lead to profound eosinophil and lymphocyte infiltration into the airways. In 
contrast to systemic immunization, mice treated with Blo t solely via the intranasal 
route had far less neutrophils in the BAL fluid, which indicates that the absence of 
exogenous adjuvant and a more physiological sensitization route (intranasal) does 
more closely resemble human asthma. In short, this data demonstrates that our current 









Figure 3.3.3 Cell infiltration in BAL fluid of Blo t-treated mice.  
Mice were sensitized on day 0 via intranasal route with either Blo t or PBS 
respectively. Consecutive intranasal challenges with either Blo t or PBS were 
conducted from day 9 to 11 and mice were sacrificed on day 14 to be examined. Cells 
from BAL fluid was harvested and stained with CD11c, Siglec-F, Ly-6G and CD3 for 
flow cytometry analysis to obtain differential cell counts of eosinophils (CD11c- 
Siglec-F+), macrophages (CD11c+ Siglec-F+ Ly-6G-), lymphocytes (CD11c- Siglec-F- 
Ly-6G- CD3+) and neutrophils (CD11c- Ly-6G+). Data is expressed as mean ± SEM 
(*p < 0.05, **p < 0.01 and ***p < 0.001 were indicated).n=12  
3.3.4 Elevated Th2 cytokine production in mediastinal lymph node  
Consistent with features described earlier, dominant Th2 cytokine production was 
detected from re-stimulated MLN cell from mice with repeated intranasal exposure of 




Blo t. As can been in Figure 3.2.2.4, IL-4, IL-5 IL-10 and IL-13 were produced in 
greatly increased level. Though a low level of IFN-γ was found in Blo t-treated mice, 
there was no significant difference when compared to control group. 
 
 
Figure 3.3.4 Cytokine production from lung draining lymph node (MLN) of Blo 
t-treated mice.  
Mice were sensitized on day 0 via intranasal route with either Blo t or PBS 
respectively. Consecutive intranasal challenges with either Blo t or PBS were 
conducted from day 9 to 11 and mice were sacrificed on day 14 to be examined. MLN 
was harvested, processed and re-stimulated with Blo t for 5 days. Cytokines in the 
supernatant were measured by ELISA. Data is expressed as mean ± SEM (*p < 0.05, 
**p < 0.01 and ***p < 0.001 were indicated, ND=Not Detectable). n=12  
3.3.5 Mucus hyper-secretion in the lung  
Another hallmark of asthma is increased mucus production from the goblet cells 
within airway epithelium. To examine this feature, perfused and fixed lungs were 
dehydrated and sections were cut at 4µm and stained with period acid Schiff’s reagent 
to visualize mucus in pink or pink-to-purple colour. As seen in Figure 3.3.5, 
mucus-secreting goblet cells could be easily identified in Blo t-treated mice while 




control airways are free of positive mucus staining. As expected, this data presents us 




Figure 3.3.5 Representative histological images of PAS staining of the lung.  
Mice were sensitized on day 0 via intranasal route with either Blo t or PBS 
respectively. Consecutive intranasal challenges with either Blo t or PBS were 
conducted from day 9 to 11 and mice were sacrificed on day 14 to be examined. 
Lungs were perfused, fixed and collected, followed by dehydration and embedding in 
the paraffin. 4 µm sections were cut and stained with periodic acid and Schiff’s 
reagent. Representative images from at least repeated and independent experiments 
were at 100× magnification.  
 
3.3.6 Airway hyper-responsiveness (AHR)  
Although serum IgE production, local cell infiltration and mucus production as well 
as cytokine profile are very important markers that researchers look for in mouse 
asthma models, AHR is equally important and indeed more widely used as a 
diagnostic tool in identifying human asthma as it more accurately reflects the lung 
function. Using increasing concentrations of methacholine (0.5-8mg/ml), airway 




resistance which was expressed as deviation from baseline (PBS) was found to be 
significantly higher in mice with repeated intransal exposure of Blo t at various 
concentrations (Fig 3.3.6), indicating that lung function of these asthma mice was 
significantly impaired.  
 
 
Fig 3.3.6 Airway hyper-responsiveness following methacholine inhalation.  
Mice were sensitized on day 0 via intranasal route with either Blo t or PBS 
respectively. Consecutive intranasal challenges with either Blo t or PBS were 
conducted from day 9 to 11. To assess AHR, on day 14 mice were heavily 
anesthetized with an anesthesia cocktail of ketamine and medetomidine. Airway 
responsiveness was measured as the change in airway resistance (RI) to increased 
concentration of nebulized methacholine (0.5–8.0mg/ml). Mice were tracheostomized 
and mechanically ventilated at a fixed breathing rate of 140 breaths/min and the 
airway resistance (RI) was recorded. Results are expressed as deviation of respective 
basal values in response to PBS. Data is expressed as mean ± SEM (*p < 0.05, **p < 
0.01 and ***p < 0.001 were indicated). n=15 
3.4 Discussion 




In this chapter, we explored two acute asthma models induced by Blo t allergen 
following different immunization protocols. Mice sensitized systemically with Blo 
t-alum exhibit a profound asthmatic phenotype as observed in the commonly used 
OVA model. Of greater clinical relevance, the protocol that employs solely 
respiratory administration of Blo t, independent of exogenous adjuvant, induces a 
comparably robust allergic response, characterized by massive eosinophil infiltration 
and mucus hyper-secretion, Th2 cytokine production in lung draining lymph node, 
elevated serum IgE and AHR upon methacholine challenge. Less neutrophil airway 
infiltration and the absence of IgG in mouse serum further confirm that this model 
better resembles of human asthma. The mouse asthma model induced by Blo t via 
respiratory sensitization and challenge successively replicates major features of 
asthma with closer clinical relevance; therefore we used this model for future 
investigation. Before moving to the next chapter, there are a few points we would like 
to stress with extra explanation.  
1. Notably, increased neutrophil infiltration (though relatively low comparing to 
systemic sensitization protocol) was observed after repeated Blo t intranasal 
exposure. This could be due to be trace endotoxin in the extracts. Nevertheless, 
it has been shown that the presence of low level of endotoxin is actually 
required to facilitate the establishment of inflammation that induces the 
allergic immune response. The complete absence of endotoxin could otherwise 
induce immune tolerance.  




2. Since we employ a rather short protocol (two weeks in total), chronic human 
asthma features such as smooth muscle remodeling, intraepithelial recruitment 
of eosinophil and sub epithelial fibrosis could not be replicated in this model. 
Nevertheless, it fits our main research interest which is to investigate the 
underlying mechanism of dust mite sensitization. Therefore, it is unlikely that 
this acute murine model would affect our study of early immune responses 
during immune priming.
 





CHAPTER 4: Characterization of Innate and Adaptive Immunity to 
Inhaled Blo t allergen  
 
4.1 Introduction  
 
IL-4 has been shown to play a critical role in directing naïve CD4 T cells into Th2 
cells which would produce IL-4 and thus propagate the polarization in a self-sustain 
fashion (Cohn et al., 2001; Coyle et al., 1995). However, an intriguing yet perplexing 
dilemma stands out here: how could this Th2 polarization take place without being 
provided with IL-4 in the first place? For years researchers have tried to solve the 
puzzle by identifying innate immune cells, other than Th2 cells, which could produce 
IL-4 in a rapid and efficient way. For example, the basophil has been recently 
proposed to be the source of IL-4 for naïve T cell differentiation upon dust mite 
sensitization (Sokol et al., 2009; Tang et al., 2010).  
In Chapter 3, we developed a murine model of dust mite allergy via respiratory 
sensitization and challenge with Blomia tropicalis (Blo t), a dust mite found at high 
frequencies in tropical and sub-tropical regions, which is also the most prevalent mite 
species in Singapore. Using Blo t as a model for dust mite allergy, we demonstrated 
that intranasal challenge with crude Blo t extract results in the development of 
characteristic features of allergic inflammation including lung eosinophilia, 
peribronchial cell infiltration, mucus hyper-secretion and airway 
hyper-responsiveness.  





In this chapter, through characterization of IL-4-producing cells during sensitization 
phase of asthmatic responses, we further investigated the capacity of Blo t in initiating 
Th2 immunity from a cellular and molecular perspective. Here we utilized 
IL-4-IRES-eGFP (4get) mice to monitor IL-4-producing cells in vivo (Mohrs et al., 
2001). In 4get mice, a knock-in replaces endogenous gene with an IL-4/IRES/eGPF 
gene (while IL-4 activity remains intact). This leads to generation of a bicistronic 
transcript under the control of endogenous regulatory elements. Cells activated to 
express IL-4 will express eGPF simultaneously, which allows reliable in vivo tracking 
of IL-4 producing innate and adaptive immune cells and enables their isolation without 
further stimulation. Moreover, cells isolated from 4get mice can also be used to report 
the competence of IL-4 production upon stimulation. In short, 4get mice serve a 
convenient and reliable tool for us to examine immune events in our model during dust 
mite sensitization stage. 
4.2 Examination of IL-4-eGFP+ cells in Blo t-immunized 4get mice 
 
Using 4get mice to trace intracellular IL-4 expression via eGPF signal, together with 
an array of conjugated fluorophore antibody staining, we studied the kinetics of 
IL-4-producing cells, namely mast cells, basophils, eosinophils and CD4 T cells 
during allergen priming phase through flow cytometry analysis. It has been reported 
three cell surface markers CD117, CD49b and FcεRIα allow us to characterize mast 
cell, basophil and eosinophil in vivo (Hammad et al., 2010). Since lung draining 
lymph node is the primary site for Th2 cell polarization during priming stage of 
asthma response, we chose MLN to examine the onset events after Blo t sensitization. 





At various time points after single intranasal exposure of Blo t (Figure 4.2.1), lung 
draining lymph node-MLN was harvested, processed and stained with CD3, CD8, 
CD4, CD117, CD49b and FcεRIα for flow cytometry analysis (Figure 4.2.2).  
 
Figure 4.2.1 Time points for MLN analysis in 4get mice after intranasal 
immunization.  
 
Figure 4.2.2 Identification of IL-4-producing cells of MLN in 4get mice. 
IL-4-producing CD4 T cells were characterized as CD3+ CD8- (CD4+, not shown here) 
and eGFP+. Basophils were characterized as CD3-, CD49b+ and eGFP+ (FcεRIα+ 
CD117-, not shown here); Mast cells were characterized as CD3-, CD49b- , eGFP+, 
FcεRIα+ CD117+; Eosinophils were characterized as CD3-, CD49b- , eGFP+, FcεRIα- 
CD117-. This flow cytometry data images were representative of at least three 
repeated and independent experiments.  
 





As can been seen in Figure 4.2.3, one single intranasal administration of Blo t resulted 
in the induction of Th2 response, indicated by the accumulation of IL-4-eGFP+ CD4 T 
cells in the lung draining LNs, in both percentage and cell number wise. Notably, 
significant increase of IL-4-eGFP+ CD4 T started from day3 which suggests it is a 
critical time point for us to study any cellular or molecular factor that influence the 
initiation of Th2 response in our model. Unexpectedly, we only observed continuous 











Figure 4.2.3 Kinetics of IL-4-eGFP+ CD4 T cells in MLN of 4get mice.  
Mice were sacrificed at different time points after single intranasal administration of 
Blo t, namely day1, day 3 and day7. MLN was collected, processed and stained with 
CD3, CD8, CD4, CD117, CD49b and FcεRIα for flow cytometry analysis. (A) 
Percentage of IL-4-eGFP CD4 T cells of total CD4 T cells at different time points. (B) 
Absolute number of IL-4-eGFP CD4 T cells at different time points. Data is expressed 
as mean ± SEM (*p < 0.05, **p < 0.01 and ***p < 0.001 were indicated). n=12 
 
Figure 4.2.4 Kinetics of IL-4-eGFP+ innate cells in MLN of 4get mice. 
Mice were sacrificed at different time points after single intranasal administration of 
Blo t, namely day1, day 3 and day7. MLN was collected, processed and stained with 
CD3, CD8, CD4, CD117, CD49b and FcεRIα. Number of basophils, mast cells and 
eosinophils were obtained through flow cytometry analysis. Data is expressed as 
mean ± SEM (*p < 0.05, **p < 0.01 and ***p < 0.001 were indicated).n=12  
 
4.3 Th2 adjuvant-like property of Blo t 
 
Since we have shown the capacity of Blo t to promote Th2 responses through 
examining the kinetics of IL-4-producing CD4 T cells, we sought to verify this Th2 
adjuvant-like property. To determine whether Blo t has an authentic Th2 adjuvant 
effect, we utilized an adoptive transfer system. DO11.10 and 4get mice (both 





homozygous knock in mice) were crossed to generate DO11.10 × 4get mice. Since 
DO11.10 mice have T cells specific for OVA and 4get mice allows convenient 
tracking of IL-4-producing cells, this DO11.10 × 4get mice enable us to monitor IL-4 
expression within OVA-specific CD4 T cells. Naïve CD4 T cells were isolated from 
DO11.10 × 4get mice and transferred into WT BALB\c naïve recipients, followed by 
intransal immunization of OVA or OVA admixed with Blo t (Figure 4.3.1). Mice 
were sacrificed three day later and MLN was harvested, processed and stained with 
CD3, CD4 and KJ1-26 (OVA-specific recognition). Compared to intranasal 
immunization with OVA alone, mice that received both OVA and Blo t had 
significantly more OVA-specific-IL-4-producing CD4 T cells in their MLN (Figure 
4.3.2). The data suggests that Blo t possesses an authentic Th2 adjuvant-like property 
in an antigen-specific way.  
 
Figure 4.3.1 Experimental design of adoptive transfer from DO11.10 × 4get mice 
mice. 
Naïve CD4 T cells were isolated from DO11.10 × 4get mice using magnetic 
separation and further purified by cell sorting (CD4+CD25-CD62L+CD44-). 2.5 
million purified cells were transferred into WT BALB\c naïve recipient via 
intravenous route. On the following day, recipient mice were immunized with either 





OVA or OVA admixed with Blo t intranasally. Mice were sacrificed three days later 
and MLN was harvested and examined through flow cytometry. 
OVA-specific-IL-4-producing cells were identified as CD3+ CD4+ KJ1-26+ eGFP+ 
cells. 
  
Figure 4.3.2 Percentage of OVA-specific-IL-4-eGFP+ CD4 T cells of total CD4 T 
cells in MLN. 
IL-4-eGFP expression by CD4 T cells from DO11.10 × 4get mice transferred into 
naïve BALB/c mice which were intranasally immunized by ovalbumin (OVA), OVA 
admixed with Blo t after adoptive transfer as described in Figure 4.3.1. KJ1.26+ CD4 
T cells in MLN were examined three days after immunization. Data is expressed as 
mean ± SEM (*p < 0.05, **p < 0.01 and ***p < 0.001 were indicated). n=9  
4.4 Discussion  
In this chapter, we studied the kinetics of IL-4-producing cells in 4get. As described 
earlier, CD4 T cells which are positive for IL-4-eGFP signal started accumulate in 
lung draining lymph nodes from day 3 onwards in mice that received a single 
administration of Blo t allergen. To further verify this Th2 adjuvant-like activity, we 





employed an adoptive transfer system and successively demonstrated that Blo t 
indeed could facilitate the differentiation of CD4 T cells to a bystander antigen. 
Meanwhile, innate cells which have been shown to possess the ability to produce IL-4 
and may play a role in initiating Th2 polarization were also examined. In contrast to 
previous reports, no significant IL-4-producing basophil accumulation was observed 
in our model. Although it was suggested in the past few years that basophils were 
crucial for the development of Th2 disease in response to allergens (Perrigoue et al., 
2009a; Sokol et al., 2009; Yoshimoto et al., 2009), other groups have shown that it 
was DCs and not basophils, that were necessary and sufficient for development of 
Th2 immunity to allergens (Hammad et al., 2010; Sullivan et al., 2011).  
Though IL-4 producing eosinophils in lung draining lymph node displayed a similar 
dynamic to CD4 T cells and we were unable to investigate the role of eosinophil in 
initiating Th2 responses during allergen sensitization stage, due to the lack of 
transgenic mice (eosinophil deficient mice). Importantly, recent published data on 
house dust mite allergen demonstrates that eosinophils are indispensable at least 
during the onset stage of Th2 immunity (Hammad et al., 2010). The IL-4 dilemma 
remains unsolved, since none of these IL-4-producing innate cells were shown to be 
critical in triggering the differentiation of naïve T cells into Th2 cells. However a 
recent study suggests that Th2 polarization might happen as a default when signals 
required for Th1 polarization are absent (Zhu et al., 2010).  
Since our research focuses on cellular and molecular factors which initiate and/or 
regulate Th2 immunity during priming stage of dust mite allergy and DCs have been 





suggested to be the ones bridging innate and adaptive immunity in asthma, we 
decided to investigate the behavior and function of DCs in our model.
 





CHAPTER 5: Lung Dendritic Cells in Th2 Immunity Induced by 
Inhaled Blo t allergen  
 
5.1 Introduction  
Although lung DCs are well described to control the induction of allergic responses to 
dust mite (Lambrecht and Hammad, 2012), it is unclear which lung DC subset is 
responsible for priming of the Th2 CD4 T cells. Lung DCs have been classically 
divided into two distinct subsets, namely, the CD103+CD11b-ve and CD11b+CD103neg 
DCs (Edelson et al., 2010; Sung et al., 2006). However, we have recently shown that 
the use of these two markers in combination with CD11c and MHCII to define the 
lung DC subsets results in substantial contamination of the CD11b+ DC population 
with interstitial macrophages (von Mutius, 2009). Using two additional markers CD24 
and CD64, bona fide lung CD11b+ DCs can be discriminated as a CD24+CD64neg 
population and the macrophages as a CD24negCD64+ population. In addition to the 
potential confounder of macrophages within CD11b+ DCs sorted from the lung tissue, 
the relative contribution of each DC subset to the pathogenesis of dust mite allergy is 
not clear. Studies using sorted ex vivo lung DCs have led to conflicting reports about 
the contribution of CD103+ and CD11b+ DCs to Th2 priming (Furuhashi et al., 2012; 
Nakano et al., 2012). In addition, although mice models exist which permit the 
selective depletion of lung CD103+ DCs (GeurtsvanKessel and Lambrecht, 2008), 





thus far there have been no mice models to specifically deplete lung CD11b+ DCs to 
assess their contribution to Th2 cell priming in response to allergen challenge. 
In previous chapters, a thorough description of the murine asthma model employing 
respiratory sensitization and challenge protocol was shown to demonstrate the strong 
allergenicity of Blo t allergen; examination of IL-4-producing CD4 T cells in 4get 
mice further emphasises the capacity of Blo t to induce a Th2 response acting as a 
Th2 adjuvant. In this chapter, we aimed to characterise the behaviour of different lung 
dendritic cell subsets in our model and investigate their specific role in contributing 
the initiation of Th2 immunity.  
5.2 Ex vivo characterization of lung dendritic cells  
Firstly, we examined the kinetics of lung dendritic cell recruitment in the draining 
lymph node-MLN, the primary site of the initiation of Th2 immunity in asthma 
response (Figure 5.2.1). Dendritic cells which migrated from lung into MLN were 
identified as CD11c+ and MHCIIhi (those CD11c+MHCIImid are lymph node resident 
DCs). Notably, significant accumulation of lung dendritic cells was observed as 
earlier as one day after mice received Blo t allergen intranasally and the recruitment 
continued until three days later. Our previous examination on 4get mice indicates 
day3 as the starting time point for Th2 differentiation in MLN (Figure 4.2.3). The 
precedent recruitment of lung DC in MLN suggests the potential function of DCs in 
triggering Th2 polarization. 
 
 






Figure 5.2.1 Kinetics of lung dendritic cells in draining lymph node.  
Mice were sacrificed at various time points, namely day1, day3 and day7, after 
receiving single intranasal administration of Blo t. MLN was collected, processed and 
stained with CD11c, MHCII, CD11b, CD64 and CD24. CD11c+MHCIIhi cells were 
recognized as dendritic cells that migrated from the lung and CD11b+ DCs were 
identified as CD11c+ MHCIIhi CD11b+ CD64- CD24+, whereas lungs CD103+ DCs 
were identified as CD11c+ MHCIIhi CD103+ CD64- CD24+. Data is expressed as mean 
± SEM (*p < 0.05, **p < 0.01 and ***p < 0.001 were indicated). n=12  
 
As explained earlier, surface marker CD64 and CD24 in combination of CD11c, 
MHCII, CD11b and CD103 enables us to achieve more sophisticated discrimination 
of dendritic cells subsets. Figure 5.2.2 displays our gating strategy in flow cytometry 
analysis. Lung CD11b+ DCs were identified as CD11c+ MHCIIhi CD11b+ CD64- 
CD24+, whereas lung CD103+ DCs were identified as CD11c+ MHCIIhi CD103+ 
CD64- CD24+. Using this gating strategy, we carried on to study the most important 
function of dendritic cells, namely antigen presentation, in Th2 immunity induced by 
inhaled Blo t allergen.  
 








Figure 5.2.2 Identification of lung dendritic cells and their recruitment in MLN. 
Mice were sacrificed 24hr later after receiving single intranasal administration of Blo 
t. Lung and MLNs were collected, processed and stained with CD11c, MHCII, CD11b, 
CD64 and CD24. CD11c+MHCIIhi cells were recognized as dendritic cells that 
migrated from the lung and CD11b+ DCs were identified as CD11c+ MHCIIhi CD11b+ 
CD64- CD24+, whereas lungs CD103+ DCs were identified as CD11c+ MHCIIhi 
CD103+ CD64- CD24+. These flow cytometry images were representative of at least 
three repeated and independent experiments.  
To analyse the relative capacity of lung DCs in taking-in and carrying antigen, we 
administrated mice via intranasal with Alexa Fluor 674-labeled OVA (OVA-AF647) 
with or without Blo t. This fluorochrome-conjugation allows us to track OVA uptake 





by different lung DCs. Mice were sacrificed 24hr later and MLN was harvested, 
followed by flow cytometry analysis (Figure 5.2.3). In the absence of Blo t, we 
observed a preferential uptake of antigen by CD11b+ DCs compared to CD103+ DCs 
and even though enhanced antigen uptake was exhibited by both DC subsets when 
Blo t was added, this difference was maintained. Although it can provide direct 
insight into the antigen-uptaking capacity of lung DCs by administrating mice with 
fluorochrome-conjugated Blo t allergens, given to the fact that Blo t extracts comprise 
hundreds of proteins with various molecular weight and chemical property, it is 













Figure 5.2.3 OVA up-taking by lung dendritic cells in MLN.  
Mice were sacrificed 24hr later after receiving single intranasal administration of 
OVA-AF647 with or without the presence of Blo t. MLN was collected, processed 
and stained with CD11c, MHCII, CD11b. (A) Gating strategy  of identifying 
uptaking of OVA-AF647 in lung dendritic cells. CD11c+MHCIIhi cells were 
recognized as dendritic cells that migrated from the lung and CD11b+ DCs were 
identified as CD11c+ MHCIIhi CD11b+, whereas lungs CD103+ DCs were identified 
as CD11c+ MHCIIhi CD11b-. OVA-AF647 signal was detected through APC channel 
in flow cytometry machine. (B) Quantification of uptaking of OVA-AF647 in lung 
dendritic cells. Data is expressed as mean ± SEM (*p < 0.05, **p < 0.01 and ***p < 
0.001 were indicated). n=12 
 
To examine if this could translate to a differential capacity to present antigen to CD4 
T cells, we sorted DCs from the MLN 3 days after immunization with OVA or OVA 
plus Blo t and cultured them with CFSE-labeled naïve OVA-specific CD4 T cells 
sorted from DO11.10 × 4get mice for 4 days. The proliferation of CD4 T cells was 
determined by CFSE dilution and IL-4 production was assessed by eGFP expression. 





Notably, we observed that only lung CD11b+ DCs from mice treated with OVA+Blo t 
were able to induce robust proliferation and differentiation of naïve CD4 T cells into 
IL-4 expressing cells (Figure 5.2.4).  
 
 
Figure 5.2.4 Antigen presentation capacity of lung dendritic cells.  
Mice were sacrificed 3 days later after receiving single intranasal administration of 
OVA or OVA admixed with Blo t. DCs were sorted from the MLN and cultured with 
CFSE-labeled naïve OVA-specific CD4 T cells purified from 4get × DO11.10 mice 
for 4 days. Antigen presentation and Th2 differentiation capacity of DC subsets was 
determined by examining CFSE dilution and IL-4-eGFP expression of OVA-specific 
CD4 T cells. This flow cytometry images were representative of at least three 
repeated and independent experiments.  
 
Taken together, these data indicate that lung CD11b+ DCs are the predominant DC 
subset that transports antigen to the MLN after Blo t administration and are superior 
in stimulating naïve CD4 T cell proliferation and differentiation into Th2 cells. 
5.3 Inhibited dendritic cell migration greatly diminishes Th2 immunity 
induced by inhaled Blo t 





We sought to investigate the contribution of DCs by migration blocking exerted by 
pertussis toxin (PTX) and most importantly, specific ablation of each subset in vivo to 
avoid the possibility of immune response modifiers introduced by cellular stress 
during isolation, cell sorting and ex vivo culture.  
PTX is known to disrupt innate immune system by inhibiting early cell recruitment 
(Bestebroer et al., 2010). Here, we sought to examine whether PTX could inhibit lung 
DC recruitment to the MLN and thereby influence Th2 differentiation. As we 
expected, PTX significantly reduced accumulation -of lung DCs were observed in 
MLN of mice immunized with Blo t via intranasal route either one day or three days 
earlier (Figure 5.3A). We continued to test this blocking effect on 4get mice. As 
shown in Figure 5.3B, the capacity of Blo t to promote Th2 differentiation indicated 
by IL-4-eGFP CD4 T cell accumulation in MLN was greatly diminished in mice 
received PTX along with Blo t administration intranasally three days earlier. Next, as 
described earlier in Chapter 4, we transferred naïve CD4 T cells from DO11.10 × 4get 
mice into naïve recipients that subsequently received OVA, OVA+Blo t or OVA+Blo 
t together with PTX via intranasal route (Figure 5.3C). Examination of MLN cells 
revealed decreased OVA-specific IL-4-eGFP CD4 T cells in mice treated PTX 
simultaneously. Together, these data suggests a significant role of lung dendritic cells 
in initiating Th2 immunity in asthma response. 
Nonetheless, studies have shown that PTX exerts unspecific inhibitory effect on the 
recruitment of many innate immune cells (Bestebroer et al., 2010). PTX inhibits the 
early recruitment of neutrophils and macrophages, and interferes with the early 





chemokine production and neutrophil chemotaxis. Thus, it is imperative for us to 
employ more specific methods for DC depletion to pinpoint the contribution of 
















Figure 5.3 Inhibited dendritic cell migration greatly diminishes Th2 immunity 
induced by inhaled Blo t.  
(A) Mice were treated with either Blo t or Blo t admixed with pertussis toxin (PTX) 
via intranasal route and sacrificed on different time points, namely day 1 and day 3. 
MLN was harvested and examined by flow cytometry. CD11c+MHCIIhi cells were 
recognized as dendritic cells that migrated from the lung. n=12 (B) 4get mice were 
treated with either Blo t or Blo t admixed with pertussis toxin (PTX) via intranasal 
route and sacrificed three days later. MLN was harvested and examined by flow 
cytometry. IL-4-producing CD4 T cells were indicated by the expression of eGFP. 
n=15. (C) IL-4-eGFP expression by CD4 T cells from DO11.10×4get mice transferred 
into naïve BALB/c mice which were intranasally immunized by OVA), OVA 
admixed with Blo t or OVA admixed with Blo t plus PTX after adoptive cell transfer. 
KJ1.26+ CD4 T cells in MLN were examined three days after immunization. n=12 
Data is expressed as mean ± SEM (*p < 0.05, **p < 0.01 and ***p < 0.001 were 
indicated). 
5.4 In vivo depletion of lung CD103+ DCs does not alter the development of 
allergic responses to Blo t. 
To address the contribution of CD103+ DCs, we utilized Langerin-DTR in which 
Langerin expressing CD103+ DCs could be efficiently ablated by injection with 
diptheria toxin (DT). Consistent with previous reports, injection of Langerin-DTR 
mice with DT resulted in the specific ablation of CD103+ DCs, but not CD11b+ DCs 
(Figure 5.4A). Firstly, we examined whether CD103+ DC depletion could affect Th2 
differentiation during allergen priming stage. Thus, we injected mice with either DT 
or PBS on the same day when mice received single inoculation of Blo t via intranasal 
route. Mice were sacrificed on day3 and MLN was harvested, followed by 





re-stimulation in the presence of Blo t. Cells were collected after five day culture and 
analysed by flow cytometry (Figure 5.4B). Notably, intracellular staining of CD4 T 
cells from MLN exhibited no differences in the levels of IL-4 secretion between mice 
received DT (CD103 depleted) and the ones received PBS (CD103 un-depleted), 
which suggests the dispensable role of CD103+ DCs in our asthma model.  
To further validate this conclusion, we performed comparison with mice received 
repeated exposure of inhaled Blo t to study the influence on asthmatic features 
brought by CD103+ DC depletion. Langerin-DTR mice injected with DT or PBS via 
intraperitoneal were sensitized on day 0 with Blo t intranasally and were challenged 
with Blo t from day 9 to day 11 daily. Three days later, mice were sacrificed; samples 
were harvested and further examined. Notably, depletion of CD103+ DCs did not alter 
the magnitude of asthmatic response. Eosinophil and lymphocyte influx into the BAL 
fluid was similar to the PBS treated group (Figure 5.4C) and the mucus 
hypersecretion was detected at a similar extent (Figure 5.4D). We also observed a 
similar production of Th2 cytokines IL-4, IL-5, IL-10 and IL-13 after restimulation of 




































Figure 5.4 In vivo depletion of lung CD103+ DCs does not alter the development 
of allergic responses to Blo t.  
(A) Absence of CD103+ lung DCs was validated by flow cytometry analysis. Lung 
tissues from Langerin-DTR mice intraperitoneally injected (i.p) with DT or PBS 24hr 
earlier were harvested, digested and examined by flow cytometry antibody staining. 
This flow cytometry data images were representative of at least three repeated and 
independent experiments. (B) Intracellular staining of IFN-γ and IL-4 in proliferating 
CD4 T cells from MLN of Langerin-DTR mice intraperitoneally injected (i.p) with 
DT or PBS and concurrently immunized with Blo t via intranasal route three days 
earlier. Harvested MLN cells were restimulated with 20ug/ml Blo t for 5 days. (C-E) 
Langerin-DTR mice with i.p DT or PBS (day 0) were sensitized on day 0 with Blo t 
or PBS and were challenged with Blo t or PBS on days 9-11. Three days later, mice 
were sacrificed and examined. (C) Differential cell counts in bronchoalveolar lavage 
(BAL) fluid were determined by flow cytometry. (D) Mucus hypersecretion were 
visualized by PAS staining from lung sections (100× magnification). (E) Levels of 
cytokines from lung draining LN cells after re-stimulation were measured by ELISA. 
Data is expressed as mean ± SEM (*p < 0.05, **p < 0.01 and ***p < 0.001 were 
indicated).n=12  
5.5 Lung CD11b+ DC deficiency abrogates the development of allergic 
responses to Blo t. 
Having ruled out a Th2 priming role of CD103+ DCs in vivo, we turned our focus to 
lung CD11b+ DCs. To specifically ablate CD11b+ DCs, we used CD11c-Cre mice 
crossed with IRF4-flox mice to ablate IRF4 expression in DCs. As homeostatic 
differentiation of lung CD11b+ DCs is critically dependent on IRF4, this results in the 
specific ablation of CD11b+ DCs while CD103+ DCs remain intact as they are 
dependent on IRF8 instead (Figure 5.5A). Likewise, firstly we studied the possible 





affect brought by CD11b+ DC deficiency on Th2 differentiation during sensitization 
phase of allergy response. Strikingly, intracellular staining of CD4 T cells from 
re-stimulated MLN not only showed attenuated IL-4 secretion but also enhanced 
IFN-γ production in CD11ccre+IRF4flox mice (CD11b+ DC deficient) compared to the 
CD11ccre-IRF4flox controls (CD11b+ DC intact) (Figure 5.5B). Consistently, when this 
comparison was conducted on mice received both sensitization and challenge of Blo t; 
we observed that CD11b+ deficient mice (CD11ccre+IRF4flox) exhibited significantly 
reduced eosinophilia in the BAL (Figure 5.5C) and mucus hyper-secretion was 
abrogated (Figure 5.5D). Th2 cytokine secretion in the supernatants of MLN cells 
re-stimulated with Blo t was also dramatically reduced (Figure 5.5E).  
To demonstrate that the specific loss of CD11b+ DCs in CD11ccre+IRF4flox mice was 
the key factor underlying the abrogation of allergic responses after Blo t challenge, we 
sorted CD103+ DCs and CD11b+ DCs from the lungs of WT mice and transferred 
them intratracheally into the lungs of CD11ccre+IRF4floxmice. Upon subsequent 
multiple challenge with Blo t, only mice that received CD11b+ DCs exhibited a Th2 
response, characterised by lung eosinophilia whereas mice that received CD103+ DCs 
did not (Fig 5.5F). We observed that the extent of eosinophilia observed was variable in 
mice that received intratracheal CD11b+ DCs, likely due to inherent unpredictable 
engraftment of adoptively transferred DCs into the lung; however, it is clear that only 
CD11b+ DCs are able to reconstitute the allergic phenotype in CD11ccre+IRF4flox mice. 
Taken together, these data suggest that CD11b+ but not CD103+ lung DCs have an 





essential role in the mediating the development of Th2 responses to dust mite 
challenge in vivo. 
In summary, these data suggest that CD11b+ but not CD103+ lung DCs have an 
essential role in the mediating the development of Th2 responses to dust mite 
challenge in vivo. 
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Figure 5.5 Lung CD11b+ DC deficiency abrogates the development of allergic 
responses to Blo t.  
(A) Absence of CD11b+ lung DCs was validated by flow cytometry analysis. Lung 
tissues and MLN from CD11ccre+IRF4flox mice and CD11ccre-IRF4flox mice 
administrated intranasally with Blo t 48hr earlier were harvested, digested and 
examined by flow cytometry antibody staining. This flow cytometry data images were 
representative of at least three repeated and independent experiments. (B) Intracellular 
staining of IFN-γ and IL-4 in proliferating CD4 T cells from MLN of 





CD11ccre+IRF4flox mice immunized with Blo t three days earlier (CD11ccre-IRF4flox as 
control). Harvested MLN cells were re-stimulated with 20ug/ml Blo t for 5 days. (C-E) 
CD11ccre+IRF4flox (CD11ccre-IRF4flox as control) were sensitized on day 0 with Blo t 
(i.n) and were challenged with Blo t (i.n) on days 9-11. Three days later, mice were 
sacrificed and examined. (C) Differential cell counts in bronchoalveolar lavage (BAL) 
fluid were determined by flow cytometry. (D) Mucus hyper-secretion was visualized 
by PAS staining from lung sections (×100 magnification). (E) Levels of cytokines 
from lung draining LN cells after re-stimulation were measured by ELISA. Data is 
expressed as mean ± SEM (*p < 0.05, **p < 0.01 and ***p < 0.001 were 
indicated).n=9 (F) CD103+ DCs and CD11b+ DCs from the lungs of WT mice and 
transferred them intratracheally into the lungs of CD11ccre+IRF4flox mice (day 0), 
followed by subsequent multiple challenge with Blo t (day 9-11). Differential cell 
counts in bronchoalveolar lavage (BAL) were analyzed on day14. (p values for this 
particular experiment: eosinophils =0.08, lymphocytes = 0.09 and n=5).  
5.6 CCR2-dependent monocyte-derived CD11b+ DCs are not required for 
the development of allergic responses to Blo t. 
Several studies have demonstrated that monocytes could contribute to the pool of 
CD11b+ DCs in the lung in steady state (Varol et al., 2007). To rule out the possible 
effect of monocyte-derived DCs (Mo-DCs) in initiating Th2 responses in the asthma 
model, we utilized chemokine receptor type 2 (CCR2) knockout mice to examine the 
role of Mo-DCs, as CCR2 is known to be required for the mobilization of monocytes 
from bone marrow into peripheral tissues (Serbina and Pamer, 2006). No difference in 
IL-4 or IFN-γ production between CCR2 knockout and WT mice was observed during 
Th2 initiation phase (Figure 5.4.4A), eosinophil infiltration (Figure 5.6B) and mucus 





hyper-secretion (Figure 5.6C)as well as cytokine profile of re-stimulated MLN cells 















Figure 5.6 CCR2-dependent monocyte-derived CD11b+ DCs are not required for 
the development of allergic responses to Blo t.  
(A) Intracellular staining of IFN-γ and IL-4 in proliferating CD4 T cells from MLN of 
CCR2 KO or WT mice immunized with Blo t three days earlier. Harvested MLN cells 
were re-stimulated with 20ug/ml Blo t for 5 days. (B-D) CCR2 KO or WT mice were 
sensitized on day 0 with Blo t (i.n) and were challenged with Blo t (i.n) on days 9-11. 
Three days later, mice were sacrificed and examined. (B) Differential cell counts in 
bronchoalveolar lavage (BAL) fluid were determined by flow cytometry. (D) Mucus 
hyper-secretion was visualized by PAS staining from lung sections (100× 
magnification). (E) Levels of cytokines from MLN cells after re-stimulation were 
measured by ELISA. Data is expressed as mean ± SEM (*p < 0.05, **p < 0.01 and 
***p < 0.001 were indicated).n=15  





5.7 Discussion  
It is becoming increasingly evident that lung DCs play a fundamental role in initiating 
the allergic response to inhaled antigens by virtue of their sentinel function and role in 
bridging the innate and adaptive immune systems. Although it was suggested several 
years earlier that basophils were crucial for the development of Th2 disease in 
response to allergens (Perrigoue et al., 2009a; Sokol et al., 2009; Yoshimoto et al., 
2009), it was later clearly demonstrated by other groups that it was DCs and not 
basophils, that were necessary and sufficient APCs for development of Th2 immunity 
to allergens (Hammad et al., 2010; Sullivan et al., 2011). Our data showing that lung 
CD11b+ DCs are crucial for initiating the Th2 response to Blo t allergens further 
underscores the notion that DCs have an indispensable role in allergic sensitization. 
While it is unequivocal that DCs play an essential role in Th2 priming, it is currently 
controversial which DC subset in the lung contributes to this process. Nakano et. al. 
showed using ex vivo isolation of DCs from the lungs of HDM challenged mice that 
CD103+ DCs selectively primed Th2 cells whereas CD11b+ DCs were responsible for 
Th1 skewing (Nakano et al., 2012). They substantiated this claim by showing that 
BXH2 mice which lack CD103+ DCs fail to mount a robust Th2 response after HDM 
treatment. In contrast, a recent study by Mesnil et. al. showed using intratracheal 
adoptive transfer that only lung CD11b+Ly6C- DCs were able to initiate allergic 
sensitization to HDM (Mesnil et al., 2012). Data from another group showed that 
CD11b+ DCs isolated from steady state lungs preferentially primed Th2 responses 
while CD103+ DCs promoted Th1 and Th17 polarization (Furuhashi et al., 2012). Our 





data supports the paradigm that CD11b+ DCs are the principal DC subset responsible 
for allergic sensitization and our conclusion is supported by the observation that ex 
vivo isolated CD11b+ DCs potently polarized Th2 cells and mice lacking CD11b+ 
DCs are refractory to dust mite challenge. While the conclusion of the study by 
Mesnil et. al. is agreement with our data, the results obtained by using adoptive 
transfer of DCs into the lung must be interpreted with caution as it has also been 
demonstrated that the adoptive transfer of bone-marrow derived DCs (Hammad et al., 
2010; Lambrecht et al., 2000; van Rijt et al., 2005b) or even splenic DCs (Sung et al., 
2001) into the lung can induce allergic sensitization. 
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CHAPTER 6: Granulocyte-Macrophage Colony-Stimulating Factor 
in the Development of Allergic Response Induced by Inhaled Blo t  
 
6.1 Introduction  
Granulocyte-macrophage colony-stimulating factor (GM-CSF) was so named because 
it could stimulate the generation of macrophage colonies and granulocytic colonies in 
agar from bone-marrow precursor cells (Metcalf, 1986). Beyond its clinic benefit in 
stimulating hematopoiesis after chemotherapy, GM-CSF has been gradually 
recognized to have pro-inflammatory activity and antibodies targeting GM-CSF or its 
receptor have being successfully tested in reducing inflammation in clinical trials 
(Hamilton, 2008).Murine models of organ-specific autoimmune diseases such as 
experimental autoimmune encephalomyelitis (EAE) and collagen-induced arthritis 
(CIA) have been utilized to study the impact of GM-CSF on chronic inflammation 
(Hamilton, 2008). The importance of GM-CSF has also been shown in the 
development of allergic asthma as blockade of GM-CSF with neutralizing antibodies 
abrogates the development of Th2 responses (Cates et al., 2004). However, the 
molecular and cellular targets of GM-CSF leading to inflammation have not been 
fully identified. It has been well recognized that GM-CSF is a pleiotropic growth 
factor that promotes the differentiation and mobilization of myeloid cells in vivo (van 
de Laar et al., 2012; Zhan et al., 2012). Besides its significant role in differentiating 
monocytes into DCs in vitro (Caux et al., 1996), evidence has also emerged that it 
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may affect the development and function of other subsets of dendritic cells. For 
example, dermal CD103+ DCs appear dependent on GM-CSF (King et al., 2010). 
However, there are multiple DC subsets with overlapping as well as distinct 
behaviour and functions in different tissues concerning both homeostasis and 
inflammatory status. What effect GM-CSF has different DC subsets has yet to be 
determined comprehensively. Furthermore, how the effect exerted by GM-CSF on 
DCs shapes immune response and eventually exhibits its critical role in 
immunopathology in vivo is not well understood. 
In Chapter 5, we have shown that lung CD11b+ DCs, not CD103+ DCs, are the ones 
initiating Th2 immunity and promote asthma responses induced by inhaled Blo t. 
Here, we sought to study the role of GM-CSF in our model: how GM-CSF potentiates 
Th2 priming and whether this effect is mediated through lung DCs, especially 
CD11b+ DCs.  
6.2 In vivo source of GM-CSF responding to inhaled Blo t  
Before we started to investigate the role of GM-CSF in our model and its effect on 
lung DCs, we examined the in vivo source of GM-CSF responding to inhaled Blo t 
allergen. It has been reported that GM-CSF can be produced by activated T cells 
(Campbell et al., 2011). Apart from T cells, many other cell types including mast cells 
(Broudy et al., 1987; Wodnar-Filipowicz et al., 1989), monocytes/macrophages 
(Lenhoff et al., 1998), endothelium cells (Broudy et al., 1987) and epithelial cells (Le 
et al., 1990)can also GM-CSF. Lung epithelium is the primary barrier between foreign 
substances in respiratory tract and underlying strolling immune cells such as 
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macrophages, neutrophils and dendritic cells. Since we primarily focus on the onset 
events of Th2 immunity in our model and dendritic cells have been shown to be 
rapidly activated and mobilized upon Blo t administration via respiratory route, 
precedent to subsequent T cell differentiation, epithelial cells in the lung is a 
reasonable candidate for being the first source of GM-CSF which exerts a regulatory 
effect on dendritic cells in an efficient way.  
Firstly, we examined the level of GM-CSF from whole lung homogenates collected 
from mice received intranasal administration of Blo t at various time points. Notably, 
an immediate increase of GM-CSF production was observed 24hr later after 
immunization but its level decreased rapidly back to basal by 48hr (Figure 6.2A). 
Next, we sought to locate the exact source of GM-CSF at such an early time point and 
epithelial cells would bear the highest possibility. Being as part of stromal cells in the 
lung, epithelial cells could be differentiated from non-stromal cells by surface marker 
CD45, which could only be found on hematopoietic stem cells-derived cells, virtually 
all the immune cells. Therefore, we separated lung cells into CD45 positive and CD45 
negative subsets via flow cytometry cell sorting and cultured them respectively 
overnight. Supernatants were harvested and ELISA was conducted to measure the 
level of GM-CSF secreted into the supernatant. As expected, we observed that 
non-haematopoietic CD45neg cells were the main source of GM-CSF and that 
CD45neg cells taken from Blo t challenge mice exhibited enhanced secretion of 
GM-CSF (Figure 6.2B). This suggested that Blo t induces lung stromal cells to 
increase GM-CSF production and this occurs shortly after Blo t inoculation. To 
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confirm epithelial cells are indeed the primary source of GM-CSF, we carried on 
performing immunohistological staining of lung sections to further verify our 
hypothesis. Through immunofluorescence staining and microscopy imaging, we 
observed increased signal of GM-CSF along the apical surface of epithelial cells 
which were identified by epithelial cell adhesion molecule(EpCAM) (Trzpis et al., 
2007) in mice received Blo t intranasally 24hr earlier (Figure 6.2C).  
Side by side, we examined some other cytokines which have been shown to exert 
certain regulatory effect on asthma responses, such as IL-33, IL-25 and TSLP 
(Allakhverdi et al., 2007; Besnard et al., 2011; Fort et al., 2001). Although we could 
readily detect other pro-Th2 cytokines such as IL-25, IL-33 and thymic stromal 
lymphopoietin (TSLP) which have been shown to be important type two 
response-driving cytokines produced by mucosal epithelia, surprisingly, we did not 
observed significant increase in their levels at 24h post challenge (Figure 6.2D). 
Overall, these data indicates a rapid production of GM-CSF by lung epithelial cells 
upon Blo t immunization and it suggests a potential role of GM-CSF in the initiation 
and development of asthma responses in our model.  
A 
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Figure 6.2 In vivo source of GM-CSF upon Blo t immunization.  
(A) Lungs were harvested from mice treated with Blo t via intranasal route at various 
time points, namely 24hr, 48hr and 72hr. Homogenized lungs were centrifuged and 
supernatant was harvested for GM-CSF ELISA assay. n=12 (B) Lungs were harvested 
from mice received Blo t inoculation intranasally 24hr earlier (control group received 
PBS). Cell sorting was performed to separate CD45-positive and CD45-negative cells. 
Sorted cells were further culture for 18hr and cell supernatant was collected for 
GM-CSF ELISA assay. n=4 (C) Immunostaining with DAPI (blue) and GM-CSF (red) 
as well as EpCAM (white) of lung sections from mice immunized with PBS and Blo t 
24hr earlier. Original magnification was 200× for lung section images of mice 
immunized by PBS or Blo t. scale bar=50µm. (representative images were shown) (D) 
Level of TSLP, IL-25 and IL-33 from lung homogenate of mice treated by Blo t or 
PBS 24hr earlier were detected through ELISA. Data is expressed as mean ± SEM (*p 
< 0.05, **p < 0.01 and ***p < 0.001 were indicated).n=12  
6.3 Lung epithelium-derived GM-CSF mediates allergic responses induced 
by Blo t 
Next, we carried on investigating the role of GM-CSF in our model, we intranasally 
administered 50µg anti-GM-CSF antibodies concurrently with Blo t. This dose of 
anti-GM-CSF was sufficient to attenuate lung-derived GM-CSF at 24h after Blo t 
challenge (Figure 6.3A).  
Firstly, we examined whether GM-CSF neutralization could affect Th2 differentiation 
during allergen priming stage. Thus, we inoculated mice intranasally with either 
anti-GM-CSF or isotype control goat IgG on the same day when mice received single 
inoculation of Blo t via intranasal route. Mice were sacrificed on day3 and MLN was 
harvested, followed by re-stimulation in the presence of Blo t. Cells were collected 
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after five day culture and analysed by flow cytometry (Figure 6.3B). Notably, 
intracellular staining of CD4 T cells from MLN exhibited significant reduction in the 
levels of IL-4 secretion from mice received anti-GM-CSF neutralization antibodies, 
comparing to the ones received isotype control, which suggests a critical role of 
GM-CSF in our asthma model.  
To further validate this conclusion, we performed comparison with mice received 
repeated exposure of inhaled Blo t to study the influence on asthmatic features 
brought by GM-CSF neutralization. Mice received anti-GM-CSF or isotype control 
on the same day of Blo t sensitization, followed by continuous challenges from day 9 
to day 11 daily. Three days later, mice were sacrificed; samples were harvested and 
further examined. Consistently, GM-CSF neutralization greatly attenuated the major 
features of asthmatic responses. Eosinophil and lymphocyte influx into the BAL fluid 
was reduced compared to the isotype treated group (Figure 6.3C) and less mucus 
secretion was observed (Figure 6.3D). Similarly, production of Th2 cytokines IL-4, 
IL-5, IL-10 and IL-13 after re-stimulation of total MLN cells was largely reduced 
upon GM-CSF neutralization (Figure 6.3E). 
Taken together, we show that GM-CSF plays a critical role in the initiation and 
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Figure 6.3 Lung epithelium-derived GM-CSF mediates allergic responses 
induced by Blo t.  
(A) Intracellular staining of IFN-γ and IL-4 in proliferating CD4 T cells from the lung 
draining LNs of mice treated with anti-GM-CSF antibodies or isotype control 
antibodies and concurrently immunized with Blo t 3 days earlier. (B-D) Mice treated 
with anti-GM-CSF antibodies or isotype control antibodies (day 0) were sensitized on 
day 0 with Blo t or PBS and were challenged with Blo t or PBS on days 9-11. 72 h 
later, mice were sacrificed and examined. (B) Differential cell counts in 
bronchoalveolar lavage (BAL) fluid were determined by flow cytometry. (C) Mucus 
secretion was visualized by PAS staining from lung sections (100× magnification). (D) 
Levels of cytokines from lung draining LN cells after re-stimulation were measured 
by ELISA. Data is expressed as mean ± SEM (*p < 0.05, **p < 0.01 and ***p < 
0.001 were indicated). n=12  
6.4 Lung epithelium-derived GM-CSF is a critical regulator of CD11b+ DC 
Th2 cell priming 
To test if GM-CSF blockade affected the ability of CD11b+ DCs to migrate to the 
MLN, we administered OVA-AF647+Blo t with anti-GM-CSF or PBS and quantified 
the percentage of CD11b+ DCs and CD103+ that were positive for OVA-AF647. We 
observed that CD11b+ DCs from anti-GM-CSF treated mice demonstrated equal 
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potential to acquire OVA-AF647 and migrate to the MLN (Figure 6.4A and Figure 
6.4B). Moreover, anti-GM-CSF treatment did not affect the expression of 
co-stimulatory molecules on CD11b+ DCs (Figure 6.4C). Therefore, it suggests that 
the attenuated Th2 responses resulted from GM-CSF blockade was not a consequence 
of reduced migration of migratory DCs to the lung LN or a modulated costimulatory 
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Figure 6.4 Neither the capacity of antigen uptake nor the expression of 
important costimulatory molecules of CD11b+ DCs was affected by GM-CSF 
neutralization.  
(A) Uptake of OVA by DC subsets in MLN cells from mice with intranasal 
administration of OVA-AF647 admixed with Blo t with either isotype control goat 
IgG or anti-GM-CSF antibodies 24 h earlier. n=20. (B) Numbers of migratory 
CD11b+DCs and CD103+DCs (recognized as CD11c+MHCIIhi) in MLN, 24hr later 
after Blo t sensitization. n=12. (C) Expression of co-stimulatory molecules in DC 
subsets in MLN cells from mice with intranasal administration of Blo t with either 
isotype control goat IgG or anti-GM-CSF antibodies 24 h earlier (representative 
images were shown). Data is expressed as mean ± SEM (*p < 0.05, **p < 0.01 and 
***p < 0.001 were indicated).  
 
To determine if the ability of GM-CSF to potentiate the allergic response was acting 
directly through lung DCs and modulated their intrinsic capacity to prime Th2 T cells, 
we sorted both DC subsets from the MLNs of mice inoculated with OVA+Blo t 
treated with either anti-GM-CSF or isotype control antibodies and evaluated their 
capacity to prime naïve CD4 T cells sorted from DO11.10 × 4get mice. Importantly, 
CD11b+ DCs from anti-GM-CSF treated mice exhibited reduced capacity for T-cell 
priming and Th2 polarization (Figure 6.5A), suggesting that CD11b+ DCs require 
GM-CSF licensing to effectively prime Th2 cells. 
Finally, we sought to determine if GM-CSF was potentiating Th2 priming directly on 
DCs or indirectly through other cells that can influence DC function such as the lung 
epithelium. To do this, we first examined the expression of GM-CSF-receptor alpha 
chain (CSFR1a) on lung CD103+ and CD11b+ DCs from mice treated with either PBS 
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or Blo t intranasally. We did not observe an overall difference between PBS and Blo t 
treated mice, nonetheless our flow cytometry analysis indicates that CD11b+ DCs 
expressed higher levels of CSFR1a in both steady state (PBS group) and 
inflammatory status (Blo t group) with similar extent (Figure 6.4B), which suggests 
GM-CSF may exert more influence upon CD11b+ DC. Next, we sorted CD11b+ DCs 
from the MLN OVA+Blo t treated mice, co-cultured the cells with naïve CD4 T cells 
sorted from 4get×DO11.10 mice and added recombinant GM-CSF. The addition of 
GM-CSF augmented the ability of CD11b+ DCs to prime naïve CD4 T cells and 
differentiate them towards a Th2 phenotype (Figure 6.4C).  
Together, these data demonstrate that lung epithelium-derived GM-CSF is a key 
factor in Th2 priming and that this effect is mediated by potentiating the capacity of 
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Figure 6.5 Lung epithelium-derived GM-CSF is a critical regulator of CD11b+ 
DC priming of Th2 cells.  
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(A) Antigen presentation and Th2 differentiation capacity of DC subsets was 
determined by examining CFSE dilution and IL-4-eGFP expression of OVA-specific 
CD4 T cells sorted from 4get × DO11.10 mice and then cultured with DC subsets 
sorted from mice immunized by OVA admixed with Blo t plus anti-GM-CSF or 
isotype control antibody. This flow cytometry data images were representative of at 
least three repeated and independent experiments. (B) Expression of 
GM-CSF-receptor alpha unique chain of CD11b+ and CD103+ DCs was determined by 
flow cytometry analysis with gating strategy illustrated. (C) Antigen presentation and 
Th2 differentiation capacity of DC subsets was determined by examining CFSE 
dilution and IL-4-eGFP expression of OVA-specific CD4 T cells sorted from 4get x 
DO11.10 mice and then cultured with DC subsets sorted from mice immunized by 
OVA admixed with Blo t, concurrently treated with rGM-CSF or not. These flow 
cytometry data images were representative of at least three repeated and independent 
experiments.  
6.5 Discussion  
It has been long known that the lung is a rich source of GM-CSF. Lung-conditioned 
medium has been widely exploited in the past as a convenient source of GM-CSF and 
the cytokine can also be readily detected in cultures of primary human bronchial 
epithelial cells. However, the excessive production of GM-CSF within the airways is 
able to break tolerance to inhaled antigen and elicit an allergic response (Hansen et al., 
1999). Consistent with this observation, it was reported that intranasal challenge with 
HDM resulted in the release of GM-CSF from lung epithelial cells (Li et al., 1998) 
and that local neutralization of lung GM-CSF by antibodies was able to markedly 
reduce lung Th2 inflammation in response to HDM (Cohn et al., 2001; Willart et al., 
2012). Although lung epithelium-derived GM-CSF has been strongly implicated as a 
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key driver of the Th2 response, it has yet to be formally demonstrated that GM-CSF 
acts directly on lung DCs to promote sensitization and not indirectly through other 
cell types within the lung parenchyma such as lung macrophages (Kotsimbos et al., 
1997). In our study, we sorted CD11b+ DCs from the MLN and showed that addition 
of recombinant GM-CSF was able to enhance antigen presentation and Th2 skewing 
of CD4 T cells. 
Although the blockade of GM-CSF presents an attractive option to inhibit allergic 
sensitization, care must be given not to perturb the balance of GM-CSF levels for lung 
homeostasis. Homeostatic levels of GM-CSF in the lung play an essential role in 
regulating multiple functions such as alveolar macrophage differentiation and 
function (Shibata et al., 2001), catabolism of surfactant proteins (Huffman et al., 
1996), and even lung DC differentiation (Greter et al., 2012). By showing a direct 
signaling effect of GM-CSF on CD11b+ DCs, we propose that the specific blockade 
of GM-CSFR on CD11b+ DCs could represent a key axis for targeted immune 
intervention during allergic sensitization. This has several advantages compared to a 
blanket, non-targeted blockade of GM-CSFR in the lung. By avoiding GM-CSFR 
blockade on macrophages, this avoids the possibility of developing alveolar 
proteinosis, and also allows for proper differentiation of lung alveolar macrophages, 
which have a critical role in innate immune defense. In addition, this avoids blocking 
GM-CSFR on CD103+ DCs which have been recently shown to require GM-CSF 
during viral infection for acquisition of optimal migratory and antigen presenting 
properties to mediate influenza virus clearance (Unkel et al., 2012). 
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In conclusion, our study demonstrates a critical role of CD11b+ DCs in the initiation 
of Th2 responses to inhaled Blo t allergens and that lung-derived GM-CSF is a key 
mediator to potentiate the ability of these DCs to prime and polarize Th2 CD4 T cells. 
Given the multi-faceted roles of GM-CSF in the function of immune cells and lung 
homeostasis, we propose that the GM-CSF-CD11b+ lung DC axis represents an 
attractive target for immune intervention in allergic patients and that targeted 
blockade of GM-CSF receptors on CD11b+ DCs is an attractive strategy to ameliorate 
sensitization to inhaled allergens while simultaneously preserving the ability of 
GM-CSF to promote immune functions within the lung.
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CHAPTER 7: Direct Instrumental effect on Dendritic Cells Exerted 
by Blo t allergen 
 
7.1 Introduction  
 
In Chapter 5, we thoroughly elucidated the differential role of lung dendritic cells 
wherein but CD11b+ but not CD103+ DCs contribute to the establishment of Th2 
responses in our murine asthma model induced by inhaled Blo t allergen. Furthermore, 
through Chapter 6 we showed that GM-CSF, a pleiotropic growth factor that 
promotes the differentiation and mobilization of myeloid cells, potentiates Th2 
priming and this effect is mediated through its licensing of lung CD11b+ DCs. 
Nevertheless, a greater understanding about the underlying molecular mechanisms 
could be obtained from in vitro experiments examining the direct effects of Blo t on 
DCs. This might enable us to identify essential molecular targets or even signalling 
pathways in the DCs responsible for bridging innate and adaptive immunity in 
asthma.  
Ideally primary lung DCs isolated and purified from mice should be used in the in 
vitro experimental procedures. However, given to the fact that numerous mice have to 
be sacrificed to gather sufficient dendritic cells (the percentage of dendritic cells in 
total lung cells is around 0.1% to 0.5%) to perform a thorough investigation, we chose 
bone marrow-derived dendritic cells (BMDCs) as a substitute in our in vitro studies. 
BMDCs have been widely used in asthma and other Th2 immune disease models 
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(Lambrecht et al., 1998; Steinfelder et al., 2009). Large number of dendritic cells can 
be generated by growing bone marrow precursors in GM-CSF, the predominant 
growth factor for DCs. Although this strategy seems highly artificial, DCs in the 
airways have a similar phenotype and are also derived from a precursor in the bone 
marrow (Gong et al., 1992; Holt et al., 1994; Holt et al., 1988). Moreover, delivering 
antigen into respiratory tract via pre-incubation BMDCs with antigen could sensitize 
mice and leads to airway inflammation after secondary exposure to inhaled antigen 
(Lambrecht et al., 1998). Thus, this model would be very useful for us to examine the 
instrumental effect exerted on dendritic cells by in vitro Blo t conditioning in the mice, 
hence deepening our understanding of the early events of sensitization to inhaled Blo t 
allergen. 
Toll-like receptors (TLRs), known being critical in the controlling initiation and class 
specification of adaptive immune responses by antigen-presenting cells (Iwasaki and 
Medzhitov, 2004). Exogenous antigen presentation by APCs in the absence of direct 
TLR stimulation generally leads to tolerance (Sporri and Sousa, 2005). Moreover, 
efficient generation of effector T-cell responses by APCs is dependent on the presence 
of TLR ligands in the phagosome containing the antigen being presented (Blander and 
Medzhitov, 2006). In recent years, studies on the underlying mechanism of 
allergenicity have revealed a significant role of TLR signaling, particularly TLR4 
pathway activation, in triggering allergic responses within various murine asthma 
models (Eisenbarth et al., 2002; Hammad et al., 2009; Piggott et al., 2005; Trompette et 
al., 2009).  
CHAPTER 7: Direct Instrumental effect on Dendritic Cells Exerted by Blo t allergen 
159 
 
In short, this chapter sought to employ BMDCs as a validated surrogate for airway 
dendritic cells to investigate the direct instrumental effect of Blo t exerting on DCs. 
7.2 Generation of GM-CSF-derived BMDCs  
BMDCs were generated from mouse bone marrow following culture in complete 
medium supplemented with GM-CSF for 6 days. BMDCs were harvested and isolated 
by positive selection using anti-CD11c magnetic beads. Cells collected before and 
after positive selection were subjected to flow cytometry analysis for CD11c and 
MHC II expression (Figure 7.2A). Percentages of cells expressing CD11c were 
summarized in Figure 7.2B. Approximately 70-80% of cells expressed CD11c after 6 
days of culture with GM-CSF, and following positive selection via α-CD11c magnetic 
beads, around 99% of the cells were positive for CD11c expression. This data proves 
that fairly pure CD11c+ MHCIIhi dendritic cells could be generated in vitro by 









Figure 7.2 Phenotyping of bone marrow-derived dendritic cells  
(A) Bone marrow cells were harvested after 6 days of culture in cRPMI supplemented 
with GM-CSF. Flow cytometric analysis of bone marrow cells before and after 
CD11c positive selection. (B) Percentages of CD11c+ expressing cells before and 
after CD11c positive selection of bone-marrow cells cultured with GM-CSF for 6 
days (Representative experiments were shown). (Courtesy of Dr Low Pey Yng) 
 
7.3 Blo t-conditioned BMDCs could promote Th2 immunity in vivo 
Before examining the effect of Blo t on DCs in vitro, we adopted a modified DC 
transfer protocol to verify that BMDCs pulsed with Blo t indeed could promote Th2 
immunity in vivo, in a similar fashion as previous studies (Lambrecht et al., 1998; 
Steinfelder et al., 2009). Mice were intratracheally (i.t) immunized with BMDCs that 
had been incubated overnight with PBS or Blo t, followed by intranasal challenge of 
Blo t for three consecutive days. Mice were sacrificed on the day after the last 
challenge and samples were collected to be examined (Figure 7.3A). As hypothesized, 
main features of asthmatic responses were successively replicated, namely profound 
eosinophil infiltration in the airway (Figure 7.3B) and predominating Th2 cytokine 
production in MLN cells (Figure 7.3C).  
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Figure 7.3 Blo t conditioned BMDCs could promote Th2 immunity in vivo  
(A) BMDC adoptive transfer and immunization protocol. Mice were intratracheally (i.t) 
immunized with BMDCs that had been incubated overnight with PBS or 100µg/ml 
Blo t (day0), followed by intranasal challenge of Blo t for three consecutive days 
(day10-day12). Mice were sacrificed on day after the last challenge (day13). (B) 
Quantitative analysis of differential cell counts in the airway. (C) Cytokine production 
of re-stimulated cells from MLN measured by ELISA. Data is expressed as mean ± 
SEM (*p < 0.05, **p < 0.01 and ***p < 0.001 were indicated). n=15  
7.4 BMDCs conditioned by Blo t allergen fail to display TLR signaling 
activation  
Next, we examined into the activation status of BMDCs pulsed by Blo t allergen in 
the aspect of toll-like receptor 4 (TLR4)-mediated signalling pathways, namely 
co-stimulatory molecule expression (CD40, CD80 and CD86) and inflammatory 
cytokine production (IL-12 and TNF-α). We employed lipopolysaccharides (LPS) 
known as a strong microbial stimuli and potent TLR4 ligand as positive control to 
achieve valid comparison. Harvested and purified BMDCs were cultured 18hr with 
Blo t extracts (LPS and PBS as controls). Supernatant was saved for cytokine 
measurement via ELISA and cells were stained with conjugated antibodies for flow 
cytometry analysis. BMDCs treated with LPS exhibited significantly enhanced 
expression of co-stimulatory molecules whereas BMDCs incubated with Blo t 
displayed similar levels of expression of CD40, CD80 and CD86 as PBS control 
(Figure 7.4A). Consistently, ELISA assay for IL-12 and TNF-α measurement 
demonstrated that only low level of inflammatory cytokines were observed in Blo t 
pulsed BMDCs, in contrast to the profound production from LPS treated group 
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(Figure 7.4B). In summary, no significant activation at least in terms of TLR4 





Figure 7.4 BMDCs conditioned by Blo t allergen fail to display TLR4 signalling 
activation  
(A) Expression of co-stimulatory molecules (CD40, CD80 and CD86) analysed by flow 
cytometry. BMDCs were incubated with PBS, 100µg/ml Blo t extracts or 50ng/ml 
LPS for 18hr. BMDCs were stained with CD11c, MHCII, CD40, CD80 and CD86. This 
representatives flow cytometry plots were gated on CD11c+MHCIIhi cells. (B) Levels of 
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IL-12p40, TNF-α measured by ELISA from the same culture as shown in Figure 7.4A. 
Data is expressed as mean ± SEM (*p < 0.05, **p < 0.01 and ***p < 0.001 were 
indicated).n=12  
 
7.5 Blo t suppresses TLR4 ligand-mediated DC activation 
The inactivated TLR4 signaling status we observed suggests Blo t might exert a 
potential counter effect against TLR4 ligand stimulation on dendritic cells. Thus, we 
stimulated BMDCs with various concentrations of Blo t extracts in the presence of 
LPS. TLR4 related co-stimulatory molecule expression and inflammatory cytokine 
production was examined as described earlier. As we predicted, Blo t displayed a dose 
dependently inhibitory activity on TLR4 ligand stimulation indicated by the inhibition 
of LPS-triggered enhanced CD40, CD80 and CD86, as well as secretion of IL-12 p40 




















Figure 7.5 Blo t suppresses TLR4 ligand-mediated DC activation  
(A-C) Expression of co-stimulatory molecules (CD40, CD80 and CD86) measured by 
median fluorescence intensity (MFI) from flow cytometry analysis and transformed 
into fold increase compared to PBS treated group. BMDCs were incubated with PBS, 
100µg/ml Blo t extracts or 50ng/ml LPS for 18hr. BMDCs were stained with CD11c, 
MHCII, CD40, CD80 and CD86. When tested in the presence of LPS, fourfold 
dilutions of Blo t extracts (200µg/ml to 12.5µg/ml) were assayed. (D) Level of 
IL-12p40 measured by ELISA from the same culture as shown in Figure 7.5A-C. 
Data is expressed as mean ± SEM (*p < 0.05, **p < 0.01 and ***p < 0.001 were 
indicated).n=15  
7.5 Discussion  
In this chapter, we employed BMDCs to study on the role of DCs in our asthma model. 
We focused on the TLR signaling pathway and demonstrated that Blo t-pulsed BMDCs 
could promote Th2 immunity in the mice, as indicated by airway eosinophilia and Th2 
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cytokine production from re-stimulated lung draining lymph node cells. Caution has 
been taken to interpret data from BMDC transfer experiment, as sensitization in 
recipient mice transferred with Blo t-treated BMDCs may be due to antigen carried by 
the BMDCs, rather than due to the antigen-presentation capacity of these DCs. Yet, 
study using OVA antigen shows that OVA-pulsed BMDCs could also promote Th2 
immunity in recipient mice whereas administration of OVA alone via intranasal route 
induces pulmonary tolerance (Akbari et al., 2001; Lambrecht et al., 1998). This 
indicates the role of transferred BMDCs in recipients is not limited as antigen carriers 
and its inherent inflammatory nature may contribute in skewing immune response to 
Th2 in vivo. Nevertheless, these Blo t treated-BMDCs failed to polarize naïve CD4 T 
cells into Th2 cells in vitro (data not shown). This phenomenon may be resulted from 
the intrinsic difference between lung resident DCs and BMDCs generated through in 
vitro culture or other factors which play a role in Th2 differentiation in vivo are required 
for polarization in vitro. 
Notably, through in vitro examination, we did not observe up-regulation of 
co-stimulatory molecules or enhanced inflammatory cytokine production involved in 
TLR4 signaling pathway in these Blo t conditioned dendritic cells. Our preliminary 
studies utilizing either LPS antagonist or TLR4 knock-out mice have suggested that 
TLR4 signaling is not required for the establishment of Th2 immunity induced by Blo t 
(data not shown).  
Investigation of the role of TLR in asthma has attracted considerable attention in recent 
years, promised by the potential in developing therapeutic agents, such as antagonists 
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for molecules involved within the signaling pathways. Studies of Der p indicates that 
Der p 2, one of the major allergens, facilitates dust mite allergy responses by its 
auto-adjuvant property, namely mimicking toll-like receptor complex protein 
(Trompette et al., 2009). Another study suggests that house dust mite allergy depends 
on the TLR4 signaling in lung epithelial cells(Hammad et al., 2009). Moreover, the 
presence of a moderate amount of LPS has been shown to be essential for breaking 
pulmonary tolerance induced by ovalbumin inhalation (Eisenbarth et al., 2002).  
The Th2-promoting activity of Schistosoma mansoni eggs and pollen allergens is 
associated with complete or partial down-regulation of TLR signaling pathways 
(Steinfelder et al., 2009; Traidl-Hoffmann et al., 2005). Consistent with our observation, 
study of Schistosoma mansoni eggs shows that certain protein components within the 
allergen could inhibit TLR4 signaling pathway in a dose dependent manner (Steinfelder 
et al., 2009). Taken together, we postulate that different signals may be involved in our 
murine model and suppression of DC activation upon TLR4 ligand stimulation raises 
the possibility that Blo t’s major effect could be inhibitory, rather than stimulatory. 
Therefore, we sought to identify the critical molecules responsible for initiating Th2 
immunity induced by Blo t allergen.
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Responsible for Inducing Th2 Immunity in vivo 
 
8.1 Introduction  
Our understanding of the mechanism(s) by which Blo t promotes Th2 responses has 
been hindered by a lack of information concerning the identity of active components 
within this dust mite that trigger Th2 polarization in vivo.  
Blo t is a very complex mixture of hundreds of proteins and glycoconjugates as well 
as lipids including structural components of the miracidial embryo as well as its 
secretory products (Chew et al., 1999). Identifying components responsible for Blo t 
allergenicity is a daunting task. Nevertheless, classic biochemical purification could 
be employed. In this chapter we describe what we have achieved so far in this 
ongoing study, as well as the difficulties we have encountered.  
Chromatography refers to a set of laboratory techniques for the separation of mixtures. 
The mixture is dissolved in a fluid called the mobile phase, which carries it through a 
structure holding another material called the stationary phase. The various 
constituents of the mixture travel at different speeds, causing them to separate. The 
separation is based on differential partitioning between the mobile and stationary 
phases. Subtle differences in a compound's partition coefficient result in differential 
retention on the stationary phase and thus changing the separation (Still et al., 1978). 
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Among various chromatographic methods, gel filtration is widely used because of its 
relative high resolution in separating different components within the mixture simply 
by their size (Paul-Dauphin et al., 2007). Typically, an aqueous solution is used to 
transport the sample through the column and in our case, phosphate buffer, which is 
close to physiological condition, is selected to be the mobile phase carrying Blo t 
extracts through the column.  
8.2 The activity of Blo t extracts in inducing asthmatic responses is 
protease sensitive 
To characterize the activity of Blo t extracts in triggering airway inflammation in vivo, 
we treated Blo t extracts with protease K, a potent enzyme that digests most proteins, 
before respiratory administration into the mice. The protein component of Blo t 
extracts appear completely digested by protease K as evaluated by Coomassie 
blue-stained SDS-PAGE (data not shown). In contrast with mice immunized by 
untreated Blo t extracts, mice repeatedly exposed to Blo t extracts treated by protease 
K did not display significantly increased numbers of inflammatory cells in the BAL 
fluid (Figure 9.2A). This phenomenon is consistent with the elimination of other 
features of allergic asthma, namely a high level of total IgE (Figure 9.2B) and 
dominant Th2 cytokine production from the MLN (Figure 9.2C) as well as mucus 
hyper-secretion (Figure 9.2D). These results suggest that protein components within 
Blo t extracts are required to trigger Th2 allergic response in vivo.  
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Figure 8.2 Components required for Blo t-induced Th2 response are protease 
sensitive.  
Mice were sensitized (day0) and challenged (day9-day11) via intranasal route as 
described before with PBS or Blo t or protease K-treated Blo t. Three days later, mice 
were sacrificed and examined. (A) Differential cell counts in bronchoalveolar lavage 
(BAL) fluid were determined by flow cytometry. (B)Total IgE in the serum was 
determined by ELISA. (C) Levels of cytokines from MLN cells after re-stimulation 
were measured by ELISA. (D) Mucus hyper-secretion was visualized by PAS staining 
from lung sections (100× magnification). Data is expressed as mean ± SEM (*p < 
0.05, **p < 0.01 and ***p < 0.001 were indicated).n=15  
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8.3 Biochemical characterization of airway allergy inducing activity in Blo 
t extracts. 
Under the premise that components within Blo t extracts responsible for inducing 
airway allergy are protease sensitive, we applied the extracts into Superdex 75 gel 
filtration column to characterize the sizes of proteins required for Blo t-induced Th2 
responses in vivo. Upon gel filtration, Blo t extracts were separated into 15 fractions 
(Figure 9.3A) which were further concentrated and tested in our murine model. After 
repeated respiratory exposure to individual fraction, only mice receiving fraction 2 
and 3 displayed significantly increased levels of eosinophil infiltration in the BAL 
fluid (Figure 9.3B). Consistently, fraction 2 and 3 were highly active in inducing Blo t 
specific Th2 cytokine production (IL-5) in lung draining lymph nodes of mice. 
However, fraction 1 and 4 also demonstrated similar activity even though mice 
receiving these two fractions did not exhibit strong airway inflammation (Figure 
9.3A), which indicates the requirement of more exquisite protein fractionation 
procedures. Coomassie blue-stained reduced SDS-PAGE reveals that these bioactive 
fractions contain relatively high molecule weigh proteins (more than 50kD) (Figure 
9.3D). Taken together, these data suggests high molecule weight protein components 
are responsible of the allergenicity of Blo t extracts.  
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Figure 8.3 Identification of Th2 response-inducing fractions from Blo t extracts.  
(A) Elution prolife derived from gel filtration. Blo t extracts applied to a Superdex 75 
10/300 GL column was eluted with 50µM phosphate buffer with 150µM NaCl 
(pH=7.0). 0.5ml fractions were collected for the length of elusion and pooled into 
fifteen bigger fractions (representative images was shown). (B) Quantitative analysis 
of cell infiltration in the airway of mice sensitized and challenged as described before 
with fractions derived from gel filtration separation or PBS as vehicle control. n=10 
(C) IL-5 produced by re-stimulated MLN cells from mice received same treatment as 
Figure9.3B was measured by ELISA. n=8 (D) Coomassie blue-stained reduced 
SDS-PAGE of active fractions 2-4 from the column, tested previously (Figure 9.3B 
and Figure 9.3C) (representative images was shown). Data is expressed as mean ± 
SEM (*p < 0.05, **p < 0.01 and ***p < 0.001 were indicated). 
8.4 Discussion 
In this ongoing study, we have verified that protein components are responsible for 
the capacity of Blo t to inducing asthma response in vivo. Gel filtration fractionation 
revealed that proteins with high molecular weight are the possible targets we were 
trying to identify. Mass spectrometry was conducted for these first four protein 
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fractions, however, overwhelming number of proteins was found with each of the 
fractions (data not shown).  
Besides the fact that there are hundreds or even thousands (not every protein has been 
discovered for Blo t) of molecules in the Blo t extract, the main problem hindering our 
identification process is the low yield of protein we eluted from the column; yet a 
relatively large amount of protein is required for successful animal sensitization and 
challenge. As alternative, now we are testing the activity of different fractions in 4get 
mice and IL-4-eGPF expression after one single Blo t administration, which allows us 
to use the least amount of protein collected.  
Yet, further data examination revealed an interesting phenomenon: all the uncovered 
Blo t allergens (from group 1 to group 21) tested positive in human patients have 
relative low molecular weight (Chan et al., 2008; Chew et al., 1999; Gao et al., 2007; 
Kidon et al., 2011), contrasting to the high molecule weight proteins we identified in 
our model. It raises the possibility that these high molecule weight proteins could be 
aggregations of smaller protein; nevertheless, none of major Blo t allergens identified 
so far has been shown to be able to induce allergy response via solely respiratory 
immunization in animals. For examples, IgE binding to the group 5 allergen, Blo t 5, 
is found to be the most prevalent among all B. tropicalis allergens. However, animal 
experiments suggest intraperitoneal injection together with alum adjuvant was 
required to achieve efficient sensitization (Chew FT, personal communication). 
Therefore, the protein components we are trying to identify might fall into another 
category of dust mite allergen: instead of being major IgE binding allergen, they 
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induce Th2 immunity in animals or even human patients by working as intrinsic 
auto-adjuvant, triggering Th2 polarization via acting on innate immune cells thereby 
facilitating isotype switch of IgE-producing B cells.
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9.1 Brief summary of our study  
Dendritic cells (DCs) are essential for the initiation of allergic immune responses. 
Lung resident DCs can be subdivided into functionally distinctive subsets, CD103+ 
and CD11b+ DCs, but it is unclear which is responsible for priming Th2 CD4 T cells. 
GM-CSF is required for the development of allergic asthma but little is known about 
how GM-CSF potentiates Th2 priming. To investigate the role of lung resident DCs in 
a novel murine asthma model induced by dust mite Blo t and how GM-CSF 
potentiates allergic asthma, we used mice wherein different lung resident DC subset is 
absent or conditionally ablated before intranasal (i.n.) Blo t immunization.  
The contribution of GM-CSF was studied in vivo and ex vivo using GM-CSF 
neutralizing Abs and recombinant GM-CSF. Respiratory sensitization and challenge 
with Blo t induced a robust allergic airway response characterized by alveolar 
eosinophil infiltration, mucus hyper-secretion, airway hyper-reactivity and Th2 
cytokine production. Blo t enhanced the uptake and presentation of ovalbumin (OVA) 
via CD11b+ lung DCs, leading to specific T-cell proliferation and Th2 differentiation. 
The absence of CD11b+, but not CD103+ lung DCs, attenuated Th2 immunity and 
allergic airway inflammation. Following Blo t sensitization, lung epithelial cells 
rapidly expressed GM-CSF and blockade of GM-CSF reduced CD11b+ lung DC 
antigen presentation and Th2 priming. Our study shows that CD11b+ lung DCs, 
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licensed by epithelial cell derived GM-CSF, play a critical role in initiation of Th2 
responses to Blo t allergens.  
 
9.2 Final discussion of our study  
Lung DCs bridge the innate and adaptive immune systems by initiating the allergic 
response to inhaled antigens through their sentinel function. Although it was 
suggested several years ago that basophils were important for the development of Th2 
responses to allergens (Perrigoue et al., 2009b; Seder et al., 1992; Sokol et al., 2009), 
it was later clearly demonstrated by other groups that DCs and not basophils were 
necessary and sufficient APCs for development of Th2 immunity to allergens 
(Hammad et al., 2010; Sullivan et al., 2011). While it is now unequivocal that DCs 
play an essential role in Th2 priming, it is still controversial which DC subset in the 
lung contributes to this process. Using ex vivo isolated DCs from the lungs of HDM 
challenged mice, Nakano et al. showed that CD103+ DCs selectively primed Th2 cells 
whereas CD11b+ DCs were responsible for Th1 skewing (Nakano et al., 2012). They 
substantiated this claim by showing that BXH2 mice, which possess a point mutation 
in the IRF8 coding region and lack CD103+ DCs, fail to mount a robust Th2 response 
after HDM treatment. As the IRF8 mutation was not solely restricted to DCs in the 
BXH2 model, care should be taken in the interpretation of these results. In contrast, 
recent studies by Mesnil et al. and Plantinga et al. using intratracheal adoptive 
transfer showed that only CD11b+ DCs were able to initiate allergic sensitization to 
HDM (Mesnil et al., 2012; Plantinga et al., 2013). In line with such observations, data 
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from another group showed that CD11b+ DCs isolated from steady state lungs 
preferentially primed Th2 responses while CD103+ DCs promoted Th1 and Th17 
polarization (Furuhashi et al., 2012). Our data showing that ex vivo isolated CD11b+ 
DCs efficiently polarized Th2 cells and that mice lacking lung tissue CD11b+ DCs are 
refractory to dust mite challenge supports the paradigm that lung tissue CD11b+ DCs 
are the principal DC subset responsible for allergic sensitization. While our data 
supports the findings of Mesnil et al. and Plantinga et al., we caution that data from 
DC adoptive transfer into the lung should be interpreted within the context of in vivo 
DC depletion experiments as it has also been demonstrated that the adoptive transfer 
of bone-marrow derived DCs (Hammad et al., 2010; Lambrecht et al., 2000; van Rijt 
et al., 2005a) or even splenic DCs (Sung et al., 2001) into the lung can induce allergic 
sensitization. 
In contrast to CD11b+ DCs which principally act early in the sensitization phase of the 
allergic response, monocyte-derived DCs appear to be involved at a later stage during 
allergen challenge as they are recruited in the inflamed tissue. Plantinga et. al. showed 
that monocyte-derived DCs could compensate for the lack of CD11b+ DCs in 
Flt3l-deficient mice, but only when a high dose of 100µg HDM was used for both 
sensitization and challenge. (Plantinga et al., 2013). They also reported that CCR2KO 
mice developed less allergic airway inflammation when exposed to a high-dose 
allergen challenge protocol. In our set up with Blo t, however, we did not observe a 
role for CCR2 dependent monocyte-derived DCs in the development of Th2 
responses even though a high dose of 100µg was used during sensitization. However, 
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it should be noted that the definition of ‘high dose’ is defined by protein amount and 
does not take into account that the actual concentration of the Th2-inducing allergens 
may vary between HDM and Blo t extracts. Further studies to compare the allergen 
content of HDM and Blo t extracts will be needed to resolve this. 
It has been long known that the lung is a rich source of GM-CSF. Lung-conditioned 
medium has been widely exploited in the past as a convenient source of GM-CSF and 
the cytokine can also be readily detected in cultures of primary human bronchial 
epithelial cells. However, excessive production of GM-CSF within the airways is able 
to break tolerance to inhaled antigen and elicit an allergic immune response (Stampfli 
et al., 1998). Consistent with this observation, it was reported that intranasal challenge 
with HDM resulted in the release of GM-CSF from lung epithelial cells (Wells et al., 
2007b) and that local neutralization of lung GM-CSF by antibodies markedly reduced 
lung Th2 inflammation (Cates et al., 2004; Willart et al., 2012). Although lung 
epithelium-derived GM-CSF has been strongly implicated as a key driver of Th2 
responses, it has yet to be formally demonstrated that GM-CSF acts through lung DCs 
to promote sensitization and not indirectly through other cell types within the lung 
parenchyma such as lung macrophages (Kotsimbos et al., 1997). In our study, we 
showed that neutralizing GM-CSF dramatically inhibited the ability of CD11b+ DCs 
to prime Th2 CD4 T cells, and conversely, that supplementation of recombinant 
GM-CSF was able to selectively enhance the proliferation and Th2 skewing of CD4 T 
cells by CD11b+ DCs and not CD103+ DCs.  
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Although blockade of GM-CSF presents an attractive target to inhibit allergic 
sensitization, care must be given not to perturb the balance of GM-CSF levels for lung 
homeostasis. Homeostatic levels of GM-CSF in the lung play an essential role in 
regulating multiple functions such as alveolar macrophage differentiation and 
function (Shibata et al., 2001), catabolism of surfactant proteins (Huffman et al., 
1996), and even lung DC differentiation (Greter et al., 2012). By showing a role for 
GM-CSF in licensing CD11b+ DCs, we propose that the specific blockade of the 
GM-CSFR signaling pathway in CD11b+ DCs by targeted drug delivery could present 
a possible strategy for immune intervention during allergic sensitization. This has 
several advantages compared to a blanket, non-targeted blockade of GM-CSF 
signaling in the lung. By avoiding GM-CSF signaling blockade on macrophages, this 
prevents the possibility of developing alveolar proteinosis, and also allows for proper 
differentiation of lung alveolar macrophages, which play a critical role in innate 
immune defense. In addition, this avoids blocking GM-CSFR signaling on CD103+ 
DCs which have been recently shown to require GM-CSF during viral infection for 
acquisition of optimal migratory and antigen presenting properties to mediate 
influenza virus clearance (Unkel et al., 2012). 
To summarize, our study demonstrates a critical role of lung tissue CD11b+ DCs in 
the initiation of Th2 responses to inhaled Blo t allergens and that lung-derived 
GM-CSF is a key mediator that potentiates their ability to prime and polarize Th2 
CD4 T cells. Given the multi-faceted roles of GM-CSF in the function of immune 
cells and lung homeostasis, we propose that the GM-CSF-CD11b+ lung DC axis 
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represents an attractive target for immune intervention in allergic patients and that 
targeted blockade of GM-CSF receptors on CD11b+ DCs is a possible strategy to 
ameliorate sensitization to inhaled allergens while simultaneously preserving the 
ability of GM-CSF to promote immune functions within the lung. 
9.3 Limitation and future direction of our study 
In this study, we have established a novel murine asthma model induced by the dust 
mite Blo t and showed that lung resident CD11b+ DCs are the principal DC subset that 
transports antigen to the draining lymph node and are superior to CD103+ DCs in Th2 
priming in ex vivo cultures. In our study, however, we utilized the OVA as the antigen 
to measure ‘antigen uptake’ as well as ‘antigen-specific’ responses to Blo t. As this 
may not accurately reflect the true extent of antigen-uptake and presentation, there is a 
necessity to refine this assay using fluorescent-labeled Blo t extracts and bona fide 
Blo t-specific T cells. On the other hand, we demonstrated that mice selectively 
deficient for CD11b+ DCs exhibited attenuated Th2 responses and more importantly 
did not develop any allergic inflammation. Conversely, mice deficient in CD103+ DCs 
exhibited similar levels of allergic responses. However, the underlying mechanisms 
behind the distinct labor division between CD11b+ DCs and CD103+ DCs in Th2 
immunity has not clearly elucidated in our study. Further examination on the 
microstructure of dendritic cell network in the lung, dynamic mobilization of different 
DC subsets upon allergen sensitization and challenge may provide in depth 
explanation of the superiority of lung resident CD11b+ DCs. Moreover, although our 
current study is mainly focused on the contribution of lung resident DCs in asthma 
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model, we also speculate that there is a possibility of antigen handover from lung 
resident DCs which migrate into draining lymph nodes to DCs residing within the 
lymph nodes. Therefore, it might be interesting to investigate the potential role of 
lymph tissue resident DCs in our further studies.  
Another important area to further investigate is the role of GM-CSF in modulating 
lung DC function. Although we also showed that lung epithelium-derived GM-CSF is 
a key factor in licensing CD11b+ DCs to induce Th2 immunity, we do not yet 
understand how GM-CSF signals in CD11b+ DCs in asthma model, or whether this is 
a direct or indirect effect on DCs. Microarray analysis from DCs sorted from mice 
treated with Blo t with or without GM-CSF neutralization could shed light on the 
molecular events and signaling pathways involved. Another possible area to explore 
will be to examine the antigen presentation capacity of lung resident CD11b+ DCs 
which is impaired upon GM-CSF blocking in vivo.    
Lastly, since our experimental investigation has proven the role of CD11b+ DCs in 
allergic sensitization in an animal model, it will be interesting to extend this study to 
the clinical setting and investigate if such a parallel observation can be made in 
humans. We proposed that lung DCs be isolated from lung resections during surgery 
and these cells can be cultured to see if they are key in initiating Th2 responses in 
CD4 T cells. We hope that further study into this area will be able to improve clinical 
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